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ABSTRACT OF THE DISSERTATION
Mechanisms of Neonatal Brain Injury in a Rat Pup Hypoxic-Ischemic Model
by
Wanqiu Chen
Doctor of Philosophy, Graduate Program in Pharmacology
Loma Linda University, December 2009
Dr. John H. Zhang, Chairperson
Perinatal hypoxic-ischemic (HI) brain injury is a major cause of acute morbidity
and chronic nemological mortality in infants and children, with a reported incidence of 2-
9 per 1000 births. The pathophyiological mechanisms leading to immature brain damage
after HI are complex and relate to the developmental stage of the brain. The objective of
our study is to understand the neonatal hypoxic-ischemic brain injury and to aid in the
development of pharmacological treatments.
Hypoxic inducible factor 1 (HIF-1) is a transcription factor which is stabilized and
activated by hypoxia. It is the most important factor involved in the cellular response to
hypoxia. However, the role of HIF-1 in the central nervous system is unclear, which has
been considered as a regulator of both prosurvival and prodeath pathways after brain
injury. Here we tested the hypothesis that acute HIF-1 inhibition early after neonatal HI
injiuy provides neuroprotection in the developing brain by preserving blood-brain barrier
(BBB), ameliorating brain edema, and reducing infarct volume via VEGF-dependent
pathway. We also investigated if matrix metalloproteinases (MMPs), one of HIF-1
downstream factors, are involved in the process of neonatal HI brain injiuy. We
hypothesized that broad-spectrum MMPs inhibition confers neuroprotection by reducing
tight junction proteins (TJPs) degradation and preserve BBB integrity. Moreover, acute
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MMPs inhibition provides long term neuroprotection and neurological function recovery
against neonatal HI brain injury.
Rice-Vannucci model of neonatal HI brain injury was used in seven-day-old rat
pups, by subjecting imilateral carotid artery ligation followed by 2 h of hypoxia (8% O2 at
37°C). Following insult, brain infarction, neuronal cell death, brain edema, elevation of
HIF-1 and MMP-2/-9 activity, elevation of VEGF and TIMP-1/-2 expression,
degradation of TJPs, along with severe brain atrophy was observed in the ipsilateral
hemisphere, which led to significant neurological deficits. HIF-1 a activity was inhibited
by 2-methoxyestradiol (2ME2,1.5, 15 or 150 mg/kg) or enhanced by
dimethyloxalylglycine (DMOG, 250 mg/kg). 2ME2 treatment exhibited dose-dependent
neuroprotection by decreasing infarct volume and reducing brain edema at 48 h post HI.
The neuroprotection was lost when 2ME2 was administered 3 h post HI. HIF-1 a
upregulation by DMOG increased the permeability of the BBB and brain edema
compared with HI group. 2ME2 (15 mg/kg) attenuated the elevation of HIF-1 a and
VEGF at 24 h after HI. 2ME2 (15 mg/kg) also had a long-term effect of protecting
against the loss of brain tissue. To investigate the role of MMPs, GM6001 (50 mg/kg or
100 mg/kg) or doxycycline (10 mg/kg or 30 mg/kg), a broad spectrum MMPs inhibitor,
was injected intraperitoneally at 2 h and 24 h after HI injury. Either GM6001 (100
mg/kg) or doxycycline (30 mg/kg) treatment attenuated brain edema and BBB disruption.
GM6001 (100 gm/kg) treatment also attenuated MMP-9/-2 activities, preserved the
degradation of tight junction proteins (TJPs), protected BBB, and provided a long term
neuroprotection morphologically and functionally.
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These results suggest that the early inhibition of HIF-1 acutely after injury
provided neuroprotection after neonatal hypoxia-ischemia which was associated with
preservation of BBB integrity, attenuation of brain edema, and neuronal death.
Meanwhile, MMPs are also involved in the neonatal HI brain injury. Early MMPs
inhibition affords both acute and long-term neuroprotection. Thus, we propose that either
early HIF-1 inhibition or a short duration of MMPs inhibition in the early stage after
neonatal HI injury may offer a promising therapeutic strategy for the prevention of the




PRODEATH OR PROSURVIVAL: TWO FACETS OF HYPOXIAINDUCIBLE
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Abstract
Hypoxia, which occurs in the brain when oxygen availability drops below the
normal level, is a major cause of perinatal hypoxic-ischemie injury (HII). The
transcriptional factor hypoxia inducible factor-1 (HIF-1) is a key regulator in the
pathophysiological response to the stress of hypoxia. Genes regulated by HIF-1 are
involved in energy metabolism, erythropoiesis, angiogenesis, vasodilatation, cell survival
and apoptosis. Compared with the adult brain, the neonatal brain is different in
physiological structure, function, cellular composition and signaling pathways related
gene activation and response after hypoxia. The purpose of this review is to determine if
developmental susceptibility of the brain after hypoxic/ischemic injury is related to HIF-
la, which also plays a pivotal role in the normal brain development. HIF-1 a regulates
both prosurvival and prodeath responses in the neonatal brain and various mechanisms
underlie the apparent contradictory effects, including duration of ischemic injury and
severity, cell-types, and/or dependent on the nature of the stimulus after HIT Studies
report an excessive induction of HIF-1 in the immatiire brain, which suggests that a cell
death promoting role of HIF may prevail. Inhibition of HIF-1 a and targeted aetivation of
its prosurvival genes appear as a favorable therapeutic strategy. However, a better
understanding of multifaceted HIF-1 function during brain development is required to
explore potential targets for ftirther therapeutic interventions in the neonate.
Introduction
Perinatal hypoxic-ischemic injury (HII) is the most important cause of acute
mortality and morbidity in newboms (Volpe, 2001). Following HII, approximately 45%
of newboms die or have permanent neurological deficits including cerebral palsy and
there are currently no effective therapies. In contrast to adult stroke, the neonate exhibits
a different response to injury. These age-dependent mechanisms of neuronal death result
in differential long term neurological consequences and outcomes.
Hypoxia-inducihle factor 1 is a transcription factor that is a pivotal regulator of
oxygen homeostasis. Downstream many HIF-1 target genes play vital roles in
developmental and physiological processes, such as angiogenesis, glucose transport, and
cell proliferation/survival. Activation of these genes by HIF-1 can lead to either
prosurvival or prodeath effects, and as such is important for the development of novel
therapeutic interventions. However, before exploring the dichotomy of HIF-1 activation it
is important to understand its role in development and perinatal brain injury.
Different Vulnerability of Developing Brain Compared with Adult Brain
Compared with the adult brain, the neonatal brain is different in physiological
stmcture, function, cellular composition and signaling pathways related gene activation
and protein expression. Likewise, the response to brain injury is also significantly
different compared to the adult. First, the blood-brain barrier (BBB) has been shown to be
more permeable to various blood-home solutes and small lipid-insoluhle molecules in the
fetal rat brain than in adults (Stewart and Hayakawa 1994; Dziegielewska et al. 1979).
Second, the response to injury and the primary mechanisms of neuronal cell death after
brain injury are different in the immature brain compared with those in the adult brain,
which may exhibit a shift from a caspase-3-mediated to a noncaspase-3 mediated
neuronal death. For example, the immature brain can accumulate more hydrogen
peroxide (H2O2) than in adult brain (Lafemina et al. 2006), and activate mast cell
migration after hypoxia-ischemia (Jin et al. 2007). Third, the neonatal brain responses to
hypoxia or neuroprotective treatments are different compared to the mature brain.
Simvastatin-dependent activation of eNOS (endothelial Nitric Oxide Synthase) has been
cited as one of the main mechanisms responsible for neuroprotection in the adult brain,
while eNOS activity is not affected by simvastatin treatment in the neonate (Cimino et al.
2005). Also, overexpression of superoxide dismutase 1, a known neuroprotectant in adult
stroke models, is not protective after HII in the neonatal mouse brain (Sheldon et al.
2007).
The immature brain is more resistant to hypoxia/ischemia than the mature brain,
which could be HIF-1-related. Lai et al. suggested that chronic postnatal hypoxia in
different ages induces differential effects on brain glycolytic and tricarboxylic acid
(TCA) cycle enzymes activities, which is likely to be mediated by HIF-1 (Lai et al. 2003).
Trollmann et al. reported the differential expression of HIF-1 and HIF-1-regulated target
genes in the different age of developing brain upon exposure to hypoxia, which implies to
be involved in the various cellular susceptibility to hypoxic distress (Trollmann et al.
2008). Resnik et al. reported that HIF-1 alpha activity differs with respect to both oxygen
sensitivity and developmental stage. They showed that in fetal pulmonary artery (PA)
smooth muscle cells (SMC), fetal HIF-1 protein levels were 02-insensitive, however in
adult PA SMC, hypoxia increased HIF-1 protein expression (Resnik et al. 2007).
Magnetic resonance imaging (MRI) has proved to be a valuable tool for
monitoring development and pathology in the neonatal brain (Ashwal et al. 2007). Within
hours to days after HIT, MRI shows increased signal intensity in the cortex and striatum
using diffusion- (DWI) and T2-weighted imaging (T2WI) (Figure 1). Compared to the
adult, there is a basal level of HIF-1 activation present in the normal neonate, which is
further increased after HII. A recent MRI study showed excellent correlation between
neuroimaging and HIF-1 expression levels suggesting that MRI could be a potential
surrogate marker (Jordan et al. 2005).
HIF-1: Regulation of Activity and Target Genes
HIF-1 is the most important factor regulating O2 homeostasis and the cellular
response to hypoxia and was purified first by Wang and Semenza in 1995 (Wang et al.
1995a). It is a heterodimeric transcription factor composed of an oxygen-regulated HIF-
la and a constitutively expressed HIF-1 p Suburiit. During normoxic conditions, the
hydroxylation of prolines in the oxygen-dependent degradation domain (ODD) of HIF-1 a
leads to degradation, while the degradation of HIF-1 a can be blocked if oxygen
availability is reduced (Figure 2). Asparaginyl hydroxylation mediated by factor
inhibiting HIF-1 (FIH) regulates HIF transactivation, while prolyl hydroxylation by
prolyl hydroxylase (PHD) regulates degradation of HIF-a chain. As illustrated in Figure 2,
modification of HIF-1 by PHD and FIH, would lead to graded levels of expression but
the co-activator p300 is required for full transcription of genes related to HIF-1. During
hypoxic conditions, HIF-1 binds to the core DNA sequence 5'-G/ACGTG-3' within
promoter/enhancer of its target genes and regulates their expression (Wang et al. 1995a).
Other than hypoxia, there are also a number of non-hypoxic stimuli which are
capable of up-regulating this transcription factor, including growth factors, cytokines,
free radicals and hormones. Major activators and inhibitors of HIF-1 activity are
presented in the Table 1. Regulation of HIF-1 activity includes: oxygen sensing, redox
status, and a variety of molecular factors and pharmacological agents (Table 1). Thus,
HIF-1 is uniquely suited for bidirectional activation of transcription factors, with
prodeath and prosurvival functions.
Role of HIF-1 in Responses of Developing Brain to Injury
The developing brain needs to effectively adapt to reduced tissue oxygen tension.
mRNAs of HIF-1 a and HIF-115 are constitutively expressed throughout the normal adult
rat (Bergeron et al. 1999;Wiener et al. 1996) and in the embryonic mouse brain (Wang et
al. 1995a). HIF-1 a is strongly expressed in the normal brain of fetus with a peak at El 9
(Royer et al. 2000). However, HIF-1 a protein fekjpression is found in the prenatal and
perinatal brain but not in the normal adult brain (Figure 1). Based on differences between
the neonatal and adult brain and HIF-1 function in neonatal and adult HII the response to
therapeutic modulation of HIF-1 should also be different. First, HIF-1 a is essential for
vascular development during embryogenesis and pathogenesis and also plays an
important role in brain development. Complete deficiency of HIF-1 a leads to
developmental arrest and lethality by El 1, with neural tube and cardiovascular
malformations and cell death within the cephalic mesenchyme (Iyer et al. 1998).
Neon ate
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Figure 1. Comparison of HIF-la staining in the neonate and adult rat. Magnetic
resonance imaging of the neonate after HII demonstrates increased signal intensity
in the cortex and striatum using diffusion- (DWI) and T2-weighted imaging (T2WI).
In the cortex of control neonates there is a significant basal level of HIF-la that is
localized to neurons (arrow). After neonatal HII and other insults there is an
increased level of expression within the cortex of the neonatal hrain that is clearly
localized to neurons and other cell types (arrows). However, in the control adult










Angiogenesis (VEGF) Erythropoiesis (EPO)
Apoptosis (BNIP3) Vasodilation (i-NOS)
Inflammation (COX-2) Cell proliferation (IGF2)
Glucose metabolism (Glut1,3)
pH regulation (CarbonicanhYdrase9)
Figure 2. Molecular cascade responsible for HIF-1 activation. Under normal
levels of p02 HIF-la is rapidly degraded via an ubiquitination pathway.
Although not well studied, moderate levels of hypoxia are known to activate
HIF-1 by a p300 independent pathway that results in limited gene
transcription. Howeyer, hypoxia induces HIF-1 by activation of p300 and
binding with both HIF-la and HlF-ip that in turn activates a hjqjoxic
response element (HRE). This molecular cascade results in full transcription
of over 70 different genes of which a few general physiological processes are
illustrated. Both activation and inhibition of HIF-1 occur via the actions of
prolyl hydroxylase (PHD) and factor inhibiting HIF-1 (FIH). PHD is sensitive
to O2 levels for activation. PHD and FIH act to activate HIF but the eo-
activator p300 is required for full transcription of genes related to HIF-1.
Table 1. Regulation of HIF-1 activity
Related Mechanisms Ref.
HIF-1 activator
Calcineurin Promotes HIF-1 a expression by
dephosphorylating RACKl and
blocking RACKl dimerization
(Liu et al. 2007)
Cytokines - eg. IL-1 p, Induce HIF-1 a mRNA expression (Westra et al. 2007)
TNF-la via PI3K pathway
Growth factors, eg. IGF-1 Prolonged HIF-1 accumulation (Chavez and Lamanna
2002)




Inhibit bydroxylation of Proline in (Ivan et al. 2001)
ODD domain
ROS Modulating upstream signaling (Bonello et al. 2007)
pathways such as hydroxylases or
phosphatases, or via NF-kappaB.
Thrombin Redox-sensitive cascade activated (Gorlach et al. 2001)
by ROS may be involved in this
response.
Vitamin E Induced the expression of the a
subunit of HIF-1
(Zhang et al. 2004)
Sodium orthovanadate,
tyrosine kinase
An inhibitor of tyrosine
phosphatases increased the basal
level of HIF-1 proteins and HIF-1
activity
(Wang et al. 1995b)
Mitogen-activated protein
kinase (MAPK)
MAPK may mediate HIF-1








YC-1 completely blocks HIF-la
expression at the post-transcriptional
level and linked with the oxygen-
sensing pathway
(Yeo et al. 2003)
HIF prolyl 4-hydroxylases Belongs to a family of iron- and 2-
oxoglutarate-dependent
dioxygenases that negatively
regulate the stability of HIF-1
(Siddiqetal. 2005)
HSP90 inhibitor - 17-
AAG
Inhibition and eventual degradation






Decreased nuclear HIF-la -binding
activity and affected the expression
of downstream genes
(Ricker et al. 2004)
Thioredoxin inhibitors Decrease HIF-la functional
transcriptional activity and DNA
binding
(Jones et al. 2006a)
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Topoisomerase(Topo)-I Repression of HIF-1 -dependent (Rapisarda et al. 2002)
inhibitors induction of gene expression
Tyrosine kinases inhibitor, Blocked the synthesis of both HIF-1 (Wang et al. 1995a)
eg. genistein subunits as well as HIF-1 DNA-
binding activity
Second, the HIF-1 a expression profile is different after HIl in different age animal.
The temporal decrease in HIF-1 expression could influence the therapeutic time window
and strategies to modulate HIF-1 in different age of animals. Third, the downstream
events regulated by HIF-1 would also be expected to have differential outcomes in the
neonatal and adult brain after HIT HIF-1 dependent activities including angiogenesis,
inflammation, apoptosis, energy metabolism, and vasomotor tone etc, will be discussed
below. Fourth, apart from being involved in normal brain development HIF-1 can affect
many aspects of perinatal brain injury and often assumes dual cellular roles, those of
prodeath and prosurvival. In adult mice with a late-stage deletion of HIF-1 a in the brain,
the predominant role in acute hypoxia is proapoptotic (Helton et al. 2005). However, in
neonatal stroke with moderate ischemia-reperfusion, HIF-1 a activation was
neuroprotective (Mu et al. 2005). The mechanisms of HIF-1 a in mediating prodeath or
prosurvival responses are not clear but are likely to play a significant role.
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HIF-la Expression in Neonatal vs. Other Stroke Models
The activation of HIF-1 by hypoxia occurs in a time and dose dependent manner
both in vivo (Yu et al. 1998) and in cell culture (Jiang et al. 1996; Wang et al. 1995a).
HIF-la is differentially regulated depending upon the different types of stimuli, severity
of the insult and the age of the animal.
In the neonatal brain, hypoxia only, is sufficient to regulate multiple molecular
mediators that may contribute, but are not sufficient, to induce long-term neuronal
damage (van den Tweel et al. 2006). When hypoxia is accompanied by a concomitant
reduction in blood flow (ischemia) are there more persistent alterations of HIF-1
expression. In 10-day-old pups after 1.5 hr middle cerebral artery (MCA) occlusion, HIF-
la protein peaks at 8 hr and declines subsequently at 24 hr in the injured cortex (Mu et al.
2003). In a postnatal 12-day rat HII model, van den Tweel et al. reported that HIF-la
proteins increased and peaked at 3 hr but returned to baseline at 6 h after injury (van den
Tweel et al. 2006). In newborn rats the cerebral cortex and hippocampus are major sites
of HIF-la mRNA expression (Bergeron et al. 1999). A study by Kaur et al. showed
enhanced mRNA and protein expression of HIF-la together with its target genes such as
VEGF, eNOS, inducible nitric oxide synthase (iNOS) and neuronal nitric oxide synthase
(nNOS) in the neonatal hippocampus as early as 3 h following hypoxia, which may be
responsible for causing damage to the dendrites and axons in the immature hippocampus
(Kaur et al. 2008). The signaling pathways responsible for the regulation of HIF-la in the
developing brain after HI have been studied. Recent reports suggest that Erk 1 /2 MAPK
and PI3K / Akt pathways are involved in HIF-la activation after neonatal HII (Li et al.
2008b; Li et al. 2008a). NF-kB is also shown to mediate HIF-la transcription (Rius et al.
2008).
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In adult rats, focal cerebral ischemia induced a robust upregulation of mRNAs
encoding HlF-la in the peri-infarct penumbra by 7.5 hr after ischemia with a 15-17-fold
increase of HlF-1 message that continued for 20 hr. Another study reported a 1.8-2.5 fold
increase in both HlF-la and HlF-lb proteins by 20 hr after reperfusion (Bergeron et al.
1999;Sharp et al. 2001). However, the durability of HlF-1 induction has been noted in
global ischemia. In the 2-vessel occlusion (VO) global ischemic model, HlF-la
expression was increased 8-24 hr after ischemia and persisted for 96 hr after reperfusion
(Jin et al. 2000; Li et al. 2005b). The prolonged HlF-la accumulation may be induced by
additional factors during the delayed reperfusion period, such as insulin-like growth
factor-1 (lGF-1), as it takes only several hours to revive tissue from hypoxia after
reperfusion (Chavez and Lamanna 2002). Meanwhile, thrombin has been implicated as a
non-hypoxic regulator of HlF-la in cultured smooth-muscle cells (Gorlach et al. 2001).
Perihematomal HlF-la protein has been shown upregulated at 3 days after intracerebral
hemorrhage without changing mRNA levels, and hirudin reduced HlF-la upregulation in
response to the presence of both thrombin and blood (Jiang et al. 2002). The expression
of HlF-la was shown to closely correlate with the duration of hemorrhage and the
amount of bleeding and its subsequent ability to induce apoptosis of neurons (Zhu et al.
2004). Additionally, pretreatment with a low dose of thrombin can reduce brain edema
after hemorrhagic stroke, which was also thought to be associated with increasing HlF-la
levels and alterations in two HlF-la target genes, transferrin (Tf) and transferrin receptor
(TfR) in the brain (Hua et al. 2003).
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Apoptosis in Perinatal Brain Injury
HIF governs a number of apoptotic genes including the Bcl-2/adenovirus EIB
19kDa-interacting protein 3 (BNIP3), NIX (also called BNIP3L) and NOXA. Of these,
BNIP3 has been demonstrated to contribute to cell injury in the developing cortex
(Sandau and Handa 2007) via a caspase-independent cell death mechanism. Although it
is known that in neonatal hrain the process of apoptosis is largely caspase-3 dependent,
Yin and others showed that targeting both types of apoptosis is a reasonable therapeutic
option for neonatal brain injury (Yin et al. 2006). Moreover, promoter analysis of rat
caspase-9 and caspase-3 showed HIF-1 binding elements (Nishiyama et al. 2001; Liu et
al. 2002).
p53 is also involved in HIF-1 governed apoptosis after induction of HII. p53
induction by HII binds with HIF-la and results in stabilization within cerebral tissues.
Neonatal HII results in HIF-la dephosphorylation with a similar pathological phenotype
underling cell death via the p53 pathway (Calvert et al. 2006). Additionally, p53 largely
contributes to an inflammatory response in the neonatal brain (Eklind et al. 2006).
Suppressing HIF-la with hyperbaric oxygen treatment remarkably attenuated HIF-la and
p53 interactions with reduced apoptosis after neonatal hypoxia-ischemia (Calvert et al.
2003; Calvert et al. 2006).
BBB, Edema and Angiogenesis
Cerebral micro vascular endothelial cells form the BBB and its tight jimctions are
critical for maintaining brain homeostasis and low permeability. Ischemia/reperfiision is
known to damage these tight junctions and lead to increased permeability changes.
Activation of HIF-la in the adult brain of dystrophic mice coupled with vascular
14
endothelial growth factor (VEGF) and VEGFR-2 up-regulation in neurons and in
endothelial cells and is correlated with changes to endothelial ZO-1 and claudin-1
expression, which might contribute to both BBB opening and increased angiogenesis
(Nico et al. 2007). HIF-la responses upon to hypoxia in the developing brain are
critically involved in vasculogenesis, neural differentiation, and brain plasticity (Curristin
et al. 2002). Reports also showed that HIF-la mediates neural progenitor cell
proliferation and differentiation (Zhao et al. 2008; Kim et al. 2008). When rats at
different ages are exposed to HII, younger animals (P7) had a more leaky BBB,
compared with older animals (P21). Therefore only in immature animals does the
severity of injury correlate with BBB opening (Muramatsu et al. 1997). No benefit of
reducing BBB permeability was observed even in PIO rats, which additionally may
suggest that alleviation of brain edema is not sufficient for improvement of outcomes in
face of an excess hypoxic signaling (Wang et al. 2007). Inhibition of HIF-la
accumulation in the neonatal brain by 2-methoxyestradiol protected the BBB from HII
which might be related to a reduction of VEGF expression in the early stage (Chen et al.
2008). Additionally, VEGF through proinflammatory actions, such as enhanced adhesion
of leukocytes to vascular walls, may be involved in periventricular white matter damage
as demonstrated in 1-day old rats (Kaur et al. 2006).
The expression of water channels in HII has received some attention possibly due
to the very acute induction of cytotoxic edema in neonates (Badaut et al. 2007). The level
of edema was foimd not to correlate with the greatest level of aquaporin (AQP) 4
expressions in the neonate brain (Badaut et al. 2007). Regions bordering the ischemic
cortex and striatum might be considered for therapeutic modulation of AQP expression
15
and could reduce edema expansion in HII. An in vitro study showed that AQP4 promotes
water flux into astrocytes during HI, whereas it promotes water flux out of astroeytes
with reoxygenation, whieh may serve as a target during different periods of hypoxic-
isehemic brain edema in neonates (Fu et al. 2007). The role of HIF-1 in aquaporin
regulation has not yet to be examined, but in adult mice with predominant brain deletion
of HIF-1 a the gene for AQP4 was upregulated (Helton et al. 2005). It has been shown
that the promoter of AQP5 also possesses HRE and is regulated by HIF-1 a (Zhou et al.
2007).
Recent studies have demonstrated that activation of HIF-1 leads to upregulation
of faetors that are essential for blood vessel formation and it is one of the primary forces
driving both physiologieal and pathological angiogenesis (Ziello et al. 2007).
Angiogenesis-related genes, sueh as VEGF, VEGFR-1, plasminogen-aetivator inhibitor-1
(PAI-1), are all target genes of HIF-1 a. Increased expression of mRNA of HIF-1 a and
VEGF precedes angiogenesis in brain of P7 rats (Huang et al. 2004). Anan and
J
colleagues showed angiogenesis can he indueed by injecting naked DNA for HIF-1 a,
HIF-2 a or COX-2 into the brain, which suggested that neovaseularization may be
indireetly achieved using a transcriptional and cytokine regulatory strategies (Anan et al.
2006). Therefore, the acute effeets of VEGF, leading to increased BBB permeability,
should be distinguished from its latent effects, that include neovaseularization and
prosurvival actions.
Inflammation (COX-2, iNOS)
Inducible NOS (iNOS) and cyclooxygenase 2 (COX-2) are HIF-1 target genes
whieh eontrihute to brain injury via inflammation induetion (Kunz et al. 2007;Mi et al.
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2007). It has been demonstrated that decreased expression of COX-2 is associated with
reduced injury in the neonatal brain (Yin et al. 2007) whereas enhanced COX-2
expression (and iNOS) accompanies neuronal loss after Hll (Yang et al. 2005). Recent
studies with COX-2 inhibitors showed a reduction of brain injury in neonates and a
subsequent amelioration of neurobehavioral outcomes. This effect appeared durable,
suggesting an effective protection of the neurovascular unit (Fathali et al. 2007). Upon
hypoxia, HlF-1 is involved in upregulation of COX-2 in endothelial cells, which
catalyzes production of eicosanoids (Cook-Johnson et al. 2006). A strong iNOS
upregulation mediated by HlF-1 was detected after focal cerebral ischemia in the adult
brain (Suzuki et al. 2002;Matrone et al. 2004). However, somewhat conflicting data
exists on the involvement of iNOS in neuroinflammation after neonatal Hll. Major
cellular sources of iNOS are astrocytes and microglia, both activated after neonatal Hll
(Bal-Price and Brown 2001; McRae et al. 1996). Recently one group reported only
marginal expression of iNOS in P12 rats after Hll (Suzuki et al. 2002;van den Tweel et al.
2005). Meanwhile, expression of iNOS was found to be unchanged after Hll (Blumberg
et al. 1999) or even significant decrease of iNOS mRNA after hypoxia in both PO and P7
age mice (Trollmarm et al. 2008). In contrast, other authors have clearly demonstrated
that excess upregulation of iNOS may contribute to the neonatal brain injury and a
selective iNOS antagonist proved effective in neonatal stroke (Ikeno et al. 2000; Tsuji et
al. 2000). It should be however emphasized that whereas 3-nitrotyrosine may contribute
to the mechanism of brain damage after Hll, an excess NO produced upon iNOS
activation can kill neurons by acute inhibition of mitochondrial respiration at cytochrome
oxidase (Mander and Brown 2004).
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Vasomotor Tone (endothelin-1, HO-1)
Endothelin-1 (ET-1) is a HIF-1 target gene (Wykoff et al. 2000). Its injurious
potential has been demonstrated in a neonatal model of epilepsy (Mateffyova et al. 2006).
ET-1 was found elevated in the amniotic fluid and suggested to be a predictive marker for
perinatal hypoxia (Xu et al. 1999). Widespread astrocytic and cerebral endotbelial
induction of ET-1 mRNA was observed in a perinatal bypoxic-iscbemic model (Tsang et
al. 2001). Although ET-1 seems to contribute to perinatal cerebral bypoperfusion the
)
actual impact of hypoxia and HlF-1 signaling is complex. The vascular contractility to
ET-1 is countered by HO-1 activation in hypoxia (Govindaraju et al. 2005; Jemigan et al.
2001). HO-1 is also a HlF-l target gene, with a multiple regulatory binding sites in its
promoter (Jones and Bergeron 2001). It is upregulated after newborn Hll but not by
hypoxia alone (Bergeron et al. 1997), thus its expression correlates with the severity of
brain insult. HO-1 elevation in macropbages may contribute to tissue vulnerability after
Hll in neonates possibly through a release of several cytotoxic molecules and local
production of bilirubin (Bergeron etal. 1997).
The Multifaceted Role of HIF-1 in Brain Protection
Prosurvival or Prodeatb?
HlF-1 is considered as a regulator of both prosurvival and prodeatb responses in
the central nervous system (CVS) (Table 2, Figure 3). As Figure 3 suggests, both hypoxia
and free radicals can activate HlF-1 and the opposing effects of HlF-la can be attributed
to the duration and severity of hypoxia and free radical levels. Mild hypoxia induces
adaptive gene expression such as EPO, Glutl and VEGF, whereas severe or sustained
hypoxia HlF-la can lead to activation of prodeatb genes, such as BN1P3, C0X2, or p53
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stabilization. In addition, with decreasing levels of p02 during ischemia there are
subsequent increases in reactive oxygen species (ROS) that may also trigger secondary
transcription factors responsible for ensuing cell death. In neonatal HII, cumulative HIF-1
activation, due to prolonged hypoxia and excess of ROS (immature antioxidant defenses)
combined with basal hypoxic signaling, may trigger prodeath responses overpowering the
effects of prosurvival genes. Several studies have shown support for HIF-1 mediating a
prosurvival response. Firstly, stimulation of HIF-1 upon preconditioning by hypoxia or
induction of HIF-1 was important for the induction of prosurvival genes (EPO, VEGF
etc) resulting in the survival of cells (Bergeron et al. 2000;Digicaylioglu and Lipton
2001;Sharp et al. 2004;Stenzel-Poore et al. 2003). Preconditioning with C0CI2 or
deferoxamine (DFX) 24 hr before hypoxia-ischemia resulted in 75 and 56% brain
protection, respectively (Bergeron et al. 2000). DFX pretreatment ameliorated
hippocampal neuronal death after in vitro oxygen-glucose deprivation (OGD) and the
protection could be reversed with transfection of anti-HIF-1 (Ferriero 2005). These
beneficial effects could be mediated by an increase of HIF-1, although the antioxidant
effects of DFX are also likely to contribute (Freret et al. 2006). Secondly, HIF-1 target
genes such as EPO and VEGF have been shown to exhibit neuroprotective effects
(Ferriero 2005). Thirdly, HIF-1-induced angiogenesis and glycolytic metabolism results
in increased delivery of oxygen and nutrition that is critical for cell survival rmder
hypoxic/ ischemic conditions (Bergeron et al. 2000).
In contrast, HIF-1 also has been shown to mediate prodeath responses. First, HTF-
1 has been shown to interact with p53 and promote neuronal cell death as p5 3-dependent
apoptosis (Halterman et al. 1999;Renton 2003). Meanwhile, embryonic stem cells
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deficient in HIF-1 failed to induce p53 and increase resistance to stress-induced cell death
(Carmeliet et al. 1998). HIF-1 has been also shown in vitro to mediate hypoxia-induced
growth arrest and apoptosis (Goda et al. 2003). A negative form of HIF-1 protected
cortical neurons fî om delayed death following HII in vitro (Halterman et al. 1999).
Secondly, HIF-1 can regulate the expression of BH3-only pro-apoptotic family members
such as BNIP3. Several studies have shown that BNIP3 is increased following cerebral
ischemia (Althaus et al. 2006;Guo et al. 2001;Schniidt-Kastner et al. 2004). Third, in vivo
HIF-1 knockout studies showed that conditional or late-stage brain depletion of HIF-1
could be neuroprotective following acute global ischemic injury (Helton et al. 2005) and
genes involved in apoptotic pathways were down-regulated in these HIF-1 knockout mice
(Helton et al., 2005). Another study, however, found that neuron specific knockdown of
HIF-1 a resulted in increased tissue damage after focal cerebral ischemia (Baranova et al.
2007). Fourth, cloning of the rat caspase-3 gene promoter demonstrated the existence of a
functional HIF-1-binding element in this promoter (Liu et al. 2002). Also, ischemia
increased HIF-1 binding-activity on the caspase-3 gene (Van Hoecke et al. 2007). After
focal ischemia, colocalization of procaspase-3 cleavage and HIF-1 a expression was
found in the penumbra and even unlesioned tissue. It suggested a causative relationship
between HIF-1 a and caspase-3 induction through fimctional binding activity to the
caspase-3 gene promoter (Van Hoecke et al. 2007). Others have suggested that the
caspase-3/HIF-l response may be dependent on the duration and severity of the ischemic
injury (Halterman and Federoff 1999). Mild hypoxia induced adaptive gene expression
can occur transiently or persistently depending on the duration of the stimulus, whereas
severe or sustained hypoxic conditions HIF-1 can promote apoptotic cell death. The
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differential response of HIF-1 to injnry could be stimulus dependent. HIF-1 responded
differently to oxidative death induced by glutathione depletion vs. DNA damage by
camptothecin in a hippocampal neuroblast cell line (Aminova et al. 2005).
The role of HIF-1 a in mediating both prodeath and prosurvival responses, is
dependent on the duration (Halterman and Federoff 1999) and types of pathological
stimuli (Aminova et al. 2005) as well as the cell type that it is induced in (Vangeison et al.
2008) (Table 2). Recently Baranova et al. reported there are two phases of HIF-la
activation after cerebral ischemia (Baranova et al. 2007). The first phase occurred
immediately after injury till 12 hr, which correlated with the upregulation of most pro-
death genes, while in the second phase of HIF-la activation, most pro-survival genes are
involved (Baranova et al. 2007). It suggests that HIF-la may play different role during
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the acute and chronic phases after ischemia.
Targeting HIF-1 and its Genes for Novel Therapies of Neonatal
Stroke
Inhibition of HIF at selected targets is a promising therapeutic approach for
neonatal HIT Studies with genetically engineered animals and siRNA therapeutics are
definitely warranted and should include careful long-term evaluation, given the
significance of HIF in brain development. In clinical settings, however, there is a need for
pharmacological tools that could be easily administered and would penetrate BBB. Many
substances that show promise in cell culture cannot effectively penetrate and often
require specially designed vectoring systems. Nano particles-based systems are an
emerging choice (Kingsley et al. 2006). Also, chemical modification of the compound
itself may lead to improved brain protection. For example, when compared with EPO,
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carbamylated EPO produced more general and more effieient neuroproteetive effeet
(Montero et al. 2007). Promising results were found for the pharmacological HIF-1
inhibitor 2-methoxyestradiol (2ME2) in neonatal HII, when administered immediately
after the brain insult reduced injury in the immature brain (Chen et al. 2008).
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Table 2. Prosurvival or prodeath role of HIF-1
References
Prosurvival role of HIF-1 and its related genes /
proteins upon prosurvival response
Preconditioning by hypoxia or reagent upregulates HIP-la (Bergeron et al. 2000;
and protects against ischemic neonatal brain injury EPO. Sharp et al. 2004;
IGF-1,, VEGF, Glut-1 Hamrick et al. 2005)
Some HIF-1-target genes may underlie neuroprotection (Digicaylioglu and Lipton
EPO, VEGF 2001 ;Ferriero 2005)
Cobalt reduces hypoxia oxidative stress by maintaining (Shrivastava et al. 2008)
higher cellular HO-1 via HIF-1 a
Heme oxygenase I (HO-1)
Neuron-specific inactivation of HlF-la increases brain Baranova et al., 2007
injury post transient focal cerebral ischemia
EPO, Glut-1, ENOLASE, VEGF, Flt-1, PAl-1, and Ang-2
Prodeath role of HIF-1 and its related genes / proteins
upon prodeath response
HlF-la signaling in primary cortical neurons elicits Halterman et al., 1999
delayed cell death involving the stabilization and increase
of p53
p53
HlF-la mediate hypoxia-induced growth arrest and (Carmeliet et al.
apoptosis 1998;Goda et al. 2003)
p21, p27, p53
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HIF-la regulate the expression of pro-apoptotic proteins (Althaus et al. 2006;
BNIP3, NIX Bruick 2000; Sowter et al.
2001)
HIF-la mediates the induction of caspase-3 in the ischemic Van Hoecke et al., 2007
brain
Caspase-3
Brain-specific knock-out of HIF-la reduces
hypoxic-ischemic damage
Helton et al., 2005
The role of HIF-1 is both prosurvival and prodeath
Depends on hypoxic duration and severity
Depends on different types of pathological stimuli
Depends on different cell types
Halterman and Federoff
1999
Aminova et al., 2005
Vangeison et al., 2008
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Figure 3. The dual role of HIF-1 function in prodeath and prosurvival
pathways. Both hypoxia and free radicals can activate HIF-1. As p02
decreases HIF-1 regulates transcription pathways that leads to activation of
prodeath genes, for example, BNIP3, C0X2 and others, or stabilization of p53.
In addition, with decreasing levels of p02 during ischemia there are
subsequent increases in reactive oxygen species (ROS) that may also trigger
secondary transcription factors responsible for ensuing cell death. However,
HIF-1 also plays a role in pro-survival pathways by transcriptionally
activating protective genes such as EPO, Glutl and VEGF. In neonatal HII,
cumulative HIF-1 activation, due to prolonged hypoxia and excess of ROS
(immature antioxidant defenses) combined with basal hypoxic signaling, may
trigger prodeath responses overpowering the effects of prosurvival genes.
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Neurovascular Unit and Blood-Brain Barrier
The EBB is a diffusion barrier which maintains homeostasis and normal
physiological function of the central nervous system. In 1885, Paul Ehrlich was the first
person who found out the existence of BBB in the brain. The BBB endothelial cells are
the major interface between blood and brain tissues which play a vital role to control the
neuronal microenvironment. In addition to endothelial cells, the neurovascular unit is
composed of astrocytes end-feet, pericytes, basal lamina, and the neurons (Figure 4). It is
believed that intact BBB are essential for the normal brain function. Therefore,
prevention of BBB leakage by protecting the l^asal lamina and tight junction proteins in
endothelial cells from degradation is a common strategy to provide a neuroprotection.
The matrix protein around the BBB can be degraded by the enzyme, matrix
metalloproteinases, which are found in all of the elements of the neurovascular imit.
Previous reports suggested that HIF-1 is involved in MMPs activation and upregulation.
MMPs are zinc-dependent endopeptidases which are capable of degrading many types of
extracellular matrix proteins and involved in the process of tissue remodeling in various
pathologic conditions, including neurological disorders. MMPs especially MMP-2 and
MMP-9 were significantly increased in the stroke patients (Montaner et al. 2001). Furin,
a proconvertase, has been suggested as one of the FHF-l downstream target genes and
activates membrane-type 1 matrix metalloproteinase (MTl-MMP) (McMahon et al.
2005). MMP-2 is expressed as pro-form; however the rate-limiting step of its activation is
by MTl-MMP, which makes MTl-MMP critical in the process. It has also been shown
that both pro-MMP-9 and active MMP-9 is upregulated following hypoxia/ischemia in
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the brain, which might be induced by VEGF (Jeon et al. 2007), TNF-a (Rosenberg et al.
1995), and IL-lb (Esteve et al. 2002) etc.
MMPs Expression in the Central Nervous System
Previous reports suggest that MMPs can be expressed during normal development
of the central nervous system. At day 11 ofmurine embryonic CNS developmental stage,
MMP-9 mRNA could be formd localized to the germinal zone of the primitive ventricular
system (Canete-Soler et al. 1995). Genetic knock-out studies further confirmed the
beneficial roles of MMPs in CNS development. MMP-9-deficient mice showed an
abnormal accumulation, delayed migration, and reduced programmed cell death of
granule precursor cells compared to wild-type control (Vaillant et al. 2003). It is also
suggested that MMP-2, -3 and -9 are expressed in the developing cerebellar cortex to
guide granule neuron migration, Purkinje cell dendritogenesis and synaptogenesis (Luo
2005). Regulation of MMPs expression and activation is complex. MMPs are synthesized
and secreted into the extracellular space as inactive form. ProMMPs are activated via the
cleavage of the pro-domain fragment by proteases plasmin, tissue plasmingogen activator,
urokinase-type plasminogen activator, or other MMPs.
MMPs expression at the basal condition was very low, and it was significantly
increased after CNS injury such as ischemia (Gasche et al. 1999), hemorrhage
(Rosenberg and Navratil 1997) and trauma (Wang et al. 2000). After permanent MCA
occlusion in the animal model, MMP-9 expression increased at 3 h after injury and
maintained up to 24 h (Asahi et al. 2000). In a global ischemia animal model, MMP-9
significantly elevated at 6 h after injury whereas the upregulation of MMP-2 was delayed







Endotffelial cell Endothelial cell
Figure 4. VEGF induction and MMPs activation within the neurovascular unit
after HI injury. The neurovascular unit is composed of endothelial cells,
astrocytes end-feet, pericytes, and basal lamina. The schematic drawing showed
that disruption of blood-brain barrier is medicated by VEGF and active MMP-2/-9.
The active MMP-2/-9 directly digested basal lamina and led to the degradation of
TJPs. VEGF-induced BBB permeability is associated with tight jimction
dysfunction.
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MMPs Function in the Central Nervous System
Previous studies suggest that MMPs, in particular MMP-2 and MMP-9, are
deleterious in the brain after stroke (Power et al. 2003;Svedin et al. 2007). Clinically,
stroke patients display significantly higher levels of MMP-2 and MMP-9 which may
correlate with outcomes (Clark et al. 1997). In acute stage after ischemic stroke, the
effeet of MMP activity is correlated to degradation of neurovascular matrix and opening
of BBB, which promotes vasogenic edema and results in neurologieal deficits. Rosenberg
et al. showed that the opening of the BBB can he partially reduced by systemie
administration of a MMP inhibitor (Rosenberg et al. 1998). The net effect of MMPs
activation is proteolytic degradation of neurovascular imit components that allows
inereased vessel permeability (Harkness et al. 2000).
It is also reported that MMPs activation induced neuronal apoptosis (Gu et al.
2002). Previous study demonstrated that ECM proteins such as laminin are important for
eell survival and prevention of apoptosis, which representing a form of cell death known
as anoikis that eells detach from their matrix (Frisch and Francis 1994). Extracullular
proteolytic cascades triggered by MMPs can disrupt the extracellular matrix, contribute to
cell detachment, and lead to anoikis-type cell death. Furthermore, treatment with a
selective MMP-9 inhibitor (SB-3CT) rescues laminin from proteolysis and blocks cell
death in transient focal ischemia (Gu et al. 2005).
In recent years, MMPs are reported to regulate synaptic plasticity in the adult
CNS, especially in the hippocampus. Meighan et al reported that MMPs are involved in
ECM remodeling and synaptic plasticity that regulate hippocampal-dependent learning in
rats (Meighan et al. 2006). Nagy et al. demonstrated that MMP-9 knockout mice had
29
behavioral impairments in hippocampal-dependent memory (Nagy et al. 2006). New
findings also suggest that MMPs may be involved in neuroblast migration to the injured
areas after stroke. In the recovery stage after focal ischemia, MMP-9 was enhanced in the
SVZ and co-Iocalized with BrdU and neuroblast markers (Lee et al. 2006). Zhao et al.
reported that MMPs inhibition at 7 days after stroke suppressed neurovascular
remodeling, exacerbated brain injury and impaired neurological functional recovery
(Zhao et al. 2006). Moreover, the delayed expression (7-14 days) of MMP-2 after
traumatic spinal cord is necessary for ECM remodeling and functional recovery (Hsu et
al. 2006).
Targeting MMPs in Animal Brain Injury Models
MMPs could be considered as the targets for developing the neuroprotective
strategy. First of all, MMP-9 knockout mice displayed reduced infarct size and less BBB
damage after focal ischemia (Asahi et al. 200lbj. However, knockout of MMP-2 in the
mice has no protective effects on acute brain injury after focal ischemia (Asahi et al.
2001a). Moreover, MMP-3 knockout mice showed less degradation of tight junction
proteins together with reduced neutrophil infiltration compared with wild-type animals
(Gumey et al. 2006).
Additionally, several experimental studies have reported that MMP inhibitors in
the acute phase provided neuroprotection in various animal stroke models, includes focal
ischemia (Rosenberg et al. 1998), intraeerebral ischemia (Rosenberg and Navratil 1997),
global ischemia (Lee et al. 2004), hemorrhagic transformation (Sumii and Lo 2002).
Treatment with MMP inhibitors or MMP neutralizing antibodies significantly reduced
infarct size and prevented BBB breakdown after focal ischemic stroke (Romanic et al.
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1998;Rosenberg et al. 1998). MMP inhibitor (BB-94) also prevented hippocampal
neuronal death after global cerebral ischemia in mice. It was also showed that MMPs
inhibition was able to decrease hemorrhagic transformation in an embolic MCA
occlusion model.
However, the dual roles of MMPs in the CNS make the therapeutic targeting of
MMPs a challenge to treat the neurological disorders. The timely and considered dose of
MMP inhibitors is encouraged to be further discovered.
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Final Remarks
The complex response of the neonatal brain to injury may lie in a profuse and
excessive induction of HIF-1 and other molecular factors throughout the brain. There are
reports of HIF-1 a and other molecular factors equally being inducted in infarcted and non
infarcted hemispheres in the neonatal HII (van den Tweel et al. 2006). Although a
plausible interpretation is that molecular mediators alone are not sufficient to induce
long-term neuronal damage further studies are needed to examine a mechanism by which
sustained HIF-1 activation is possible and whereby discrete damage occurs to synaptic
apparatus or cell organellae in non-infarcted tissues.
Besides, most frequently used models of neonatal hypoxia ischemia may not be
perfectly accurate for modeling clinically relevant perinatal brain injury. Duration of
hypoxia affecting human immature brain in many cases is longer than 90-120 min
commonly used in animal models. Clinically, HII in some cases occurs in utero and
extends into the postnatal period (Perlman 2006).
It has been postulated that the duration of hypoxia correlates with the period of
time during which HIF remains elevated in the cells (so called "memory of HIF") (Kamat
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et al. 2007). In a prolonged maternal hypoxia model, cellular injury is barely detectable in
neonate brains at birth, however significant disturbances of brain architecture, and
impaired brain function are seen months after the insult (Golan et al. 2004b;Golan et al.
2004a). Therefore, given that HlF-1 has the potential to carry prodeath signals, its role in
chronic and latent responses to perinatal brain injury need to be further explored.
Conclusion
The developmental susceptibility of the brain after hypoxic/ischemic injury is
likely to be related to HlF-la, which plays a pivotal role in the development of injury and
in normal brain development. To explore potential targets for further therapeutic
intervention a better understanding of HlF-la function, the importance of its target genes
during the developmental stage, and further identification of fundamental differences
between the neonate and adult brain is required.
Specific Aims
The objective of our study is to understand the neonatal hypoxic-ischemic (HI)
brain injury and to aid in the development of pharmacological treatments. Based on our
preliminary results and publications by others, we have two aims to address our
hypothesis.
Specific Aim 1 is to determine whether acute HlF-la inhibition early after neonatal
hypoxic ischemic brain injury confers neuroprotection. Our specific hypothesis is that
acute HlF-1 inhibition early after HI injury provides neuroprotection in the developing
brain by preserving blood-brain barrier, ameliorating brain edema, and reducing infarct
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volume by VEGF-dependent pathway. Interventions such as pharmacological inhibition
or activation pf HIF-1 are expected to abolish or enhance neonatal HI injury.
Sub aim la: To determine whether HIF-1 inhibition confers neuroprotection in the
acute phase after neonatal HI brain injury.
Sub aim lb: To determine whether neuroprotection by HIF-1 inhibition is VEGF-
dependent. Pharmacological activation of HIF-1 will increase VEGF expression
and hamper the brain injury.
Sub aim Ic: To determine whether HIF-1 inhibition provides long term
neuroprotection against neonatal HI brain injury.
Specific Aim 2 is to examine the role of matrix metalloproteinases, one of HIF-1
downstream genes, in the developing brain after HI injury. Our specific hypothesis is that
broad-spectrum matrix metalloproteinase inhibition preserves BBB, reduces brain edema
formation and improves neurological function after neonatal hypoxic-ischemic brain
injury.
Sub aim 2a: To characterize endogenous MMP-2/-9 and their intrinsic inhibitors
TIMP-1/-2 expression profile following HI.
Sub aim 2b: To identify whether MMPs inhibition confers neuroprotection in the
acute stage after neonatal HI injury. We hypothesize that pharmacological
inhibition of MMPs activation will reduce TJPs degradation and preserve BBB
integrity.
Sub aim 2c: To determine whether acute MMPs inhibition provides long term
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Abstract
Hypoxia-inducible factor-1 alpha (HIF-la) has been considered as a regulator of
both prosurvival and prodeath pathways in the nervous system. The present study was
designed to elucidate the role of HIF-la in neonatal hypoxic-ischemic (HI) brain injury.
Rice-Vannucci model of neonatal hypoxic-ischemic brain injury was used in seven-day-
old rats, by subjecting unilateral carotid artery ligation followed by 2h of hypoxia (8%
02 at 37°C). HIF-la activity was inhibited by 2-methoxyestradiol (2ME2) and enhanced
by dimethyloxalylglycine (DMOG). Results showed that 2ME2 exhibited dose-dependent
neuroprotection by decreasing infarct volume and reducing brain edema at 48 h post HI.
The neuroprotection was lost when 2ME2 was administered 3 h post HI. HlF-la
upregulation by DMOG increased the permeability of the BBB and brain edema
compared with HI group. 2ME2 attenuated the increase in HIF-la and VEGF 24 h after
HI. 2ME2 also had a long-term effect of protecting against the loss of brain tissue. The
study showed that the early inhibition of HIF-ld acutely after injury provided
neuroprotection after neonatal hypoxia-ischemia which was associated with preservation
of BBB integrity, attenuation of brain edema, and neuronal death.
Introduction
Perinatal hypoxic-ischemic brain injury is a major cause of morbidity and
mortality in infants and children, with a reported incidence of 2-9 per 1000 births
(Vannucci 1990; Gomella, 1999). Furthermore, 20-50% of the infants suffering from
hypoxic-ischemic encephalopathy died during the newborn period and up to 25%
suffered permanent brain damage (Vannucci et al. 1999).
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Hypoxia-inducible factor 1 d (HIF-1 a) is an important transcriptional factor
implicated in many cerebrovascular pathological disorders (Semenza 2001). Several
critical signaling proteins and enzymes, such as cyclooxygenase-2, inducible nitric oxide
synthase (iNOS), vascular endothelial growth factor (VEGF) and erythropoietin, are
known to be target genes of HIF-la (Ran et al. 2005).
HIF-la upregulation by preconditioning paradigms with hypoxia and other known
preconditioning agents such as deferoxamine and cobalt chloride has been suggested to
be neuroprotective after cerebral ischemic injury (Kerendi et al. 2005; Jones et al.
2006bjRan et al. 2005;Mu et al. 2003;Bergeron et al. 2000;Sharp et al. 2004). HIF-la,
however, is also known to be increased by cerebral ischemia itself. The effects of HIF-la
manipulation by post-treatment have only recently started gathering interest. Recent
reports have suggested that HIF-la inhibition after cerebral ischemia imparts
neuroprotection in adult experimental models (Chang et al. 2007;Chen et al. 2007). A
study of brain-specific knockouts of HIF-la in mice after hypoxic injury suggested that
HIF-la is implicated in brain damage and decreasing the level of HIF-la could be
neuroprotective (Helton et al. 2005). Thus, HIF-la seems to be capable of playing a dual
role by activating both pro-death and anti-apoptotic pathways (Chang et al. 2007;Chen et
al. 2007;Helton et al. 2005;Baranova et al. 2007). Baranova et al. have recently shown a
biphasic time course for the regulation of HIF-la activation after cerebral ischemia
(Baranova et al. 2007). The first phase activation occurred acutely after injury lasted 12
hours and was involved with the upregulation of mostly pro-death HIF-la target genes.
In contrast, these genes remained rmchanged during the second phase of HIF-1 a
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activation, beginning at 24 hours and lasting up to 10 days. Thus, acute inhibition of HIF-
la is likely to be beneficial in cerebral ischemic injuries.
The present study was designed to clarify the role of HIF-1 a in the neonatal brain
after hypoxic-ischemic insult. We hypothesized that acute inhibition of HIF-la provides
neuroprotection against neonatal hypoxia-ischemia (HI). 2-niethoxyestradioI (2ME2) is
an estradiol derivative and a known HIF-la inhibitor (Mabjeesh et al. 2003;Hagen et al.
2004). On the other hand, HIF-la activity can be enhanced by suppression of prolyl and
asparaginyl hydroxylase activity by dimethyloxalylglycine (DMOG) (Milkiewicz et al.
2004). To test our hypothesis we administered 2ME2 and DMOG separately as post-
treatments in the established Rice-Vannucci neonatal HI rat model.
Materials and Methods
Animal Modeling
The experimental protocol was approved by the Institutional Committee for
Animal Care and Handling. Timed pregnant female Sprague-Dawley (SD) rats were
obtained from Harlan Laboratories, Indianapolis, IN, and housed in individual cages. The
day of birth was considered day 0. After birth, pups were housed with their dam under a
12:12-hour light-dark cycle, with food and water available ad libitum throughout the
study.
A modified Rice-Vannucci model (Rice, III et al. 1981) was adopted as follows
(Calvert et al. 2006): 7-day-old postnatal pups were anesthetized with isoflurane (3% in a
mixture of medical air and oxygen 70:30 ratio). The right common carotid artery of each
pup was identified, exposed, and permanently ligated with 5-0 surgical silk through a
near-midline incision. The wound was closed and the pups were allowed to recover from
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the anesthesia after the procedure, which roughly lasted 5 min per pup. After recovering
in their dams for 2 h, the pups were then placed in a jar perfused with a humidified and
prewarmed gas mixture (8% oxygen balanced with nitrogen) for 2 h. A constant
temperature of 37°C was maintained throughout all the procedures. After hypoxia, the
animals returned to their dams and the ambient temperature was maintained at 37°C for
24 h. Sham animals vmderwent anesthesia and the common carotid artery was exposed
without ligation and hypoxia.
Drug Administration
2ME2 (Sigma-Aldrich Corp, MO), a HIF-la inhibitor, was administered
intraperitoneally in three dosages of 1.5 mg/kg, 15 mg/kg and 150 mg/kg 5 min after HI.
It is a lipophilic compound that was constituted in dimethyl sulfoxide (DMSG) as a stock
solution and, fiirther diluted in phosphate buffer saline (PBS) (Yan et al. 2006) to a final
volume of 100 pi just before administration (filial concentration of DMSG < 1%). To
assess the window period for effective treatment, 2ME2 (15 mg/kg) was also
administered at 3 h after HI. Dimethyloxalylglycine (DMGG), a HIF-la activator was
dissolved in saline and administered intraperitoneally (250 mg / kg, Alexis Biochemicals,
CA, USA) 5 min after HI (Milkiewicz et al. 2004). The non-treated HI group received
DMSG diluted with PBS at the same volume as the treatment group.
Brain Water Content
Pups were sacrificed imder deep anesthesia and the brains were removed at 48 h
after HI. The hemispheres were separated by a midline incision and weighed on a high
precision balance (Denver Instrument, sensitivity ± 0.001 g) immediately after removal
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(wet weight) and again after drying in an oven at 105°C for 24 h as described by others
(Xi et al. 2002). The cerebellum was also weighed as control for the method. The
percentage of water content was calculated as [(wet weight-dry weight) / wet weight] x
100%.
Histology and Immunohistochemistry
At 24 h, 48 h and 2 weeks post-HI, animals were perfused imder deep anesthesia
with PBS followed by 4% paraformaldehyde. The brains were then removed and post-
fixed in formalin. Paraffin-embedded brains were sectioned into 10-pm-thick slices by
cryostat (CM3050S; Leica Microsystems). Nissl staining followed the standard protocol
for the brains at 48 h and 2 weeks after HI (Calvert et al. 2003). Immunohistochemistry
was performed (Zhou et al. 2004) at 24 h after HI using the following primary antibodies:
rabbit polyclonal anti-HIF-la (Santa Cruz Biotechnology, sc-10790,1:300), rabbit
polyclonal anti-VEGF (Santa Cruz Biotechnology, sc-507,1:300). IgG staining used for
detecting BBB breakdown was performed at 24h after HI and conjugated goat anti-rat
IgG-biotin (sc-2041; Santa Cruz Biotechnology) was used.
Infarct Volume Measurement
2,3,5-triphenyltetrazolium chloride monohydrate (TTC) staining was used to
measure infarct volume as previously described (Yin et al. 2003). Briefly, at 48 h after HI,
animals were perfused transcardially with PBS imder deep anesthesia. The brains were
removed and sectioned into 2 mm slices, then immersed into 2% TTC solution at 37°C
for 5 min, followed by 10% formaldehyde. The infarct volume was traced and analyzed
by Image J software (NIH), version 1.32.
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Western Blotting
Western Blot analysis was performed as described previously (Ostrowski et al.
2005). Animals were euthanized at 24 h after HI (n=8 for each group). Brains were
removed and stored at -80°C immediately until analysis. Protein extraction from whole-
cell lysates were obtained by gently homogenizing in RIPA lysis buffer (Santa Cruz
Biotechnology, sc-24948) and further centrifuged at 14,000g at 4°C for 30 min. The
supernatant was used as whole cell protein extract and the protein concentration was
determined by using a detergent compatible assay (Bio-Rad, Dc protein assay). Equal
amounts of protein (50 pg) were loaded on an SDS-PAGE gel. After being
electrophoresed and transferred to a nitrocellulose membrane, membrane was then
blocked and incubated with the primary antibody overnight at 4°C. The primary
antibodies used were rabbit polyclonal anti-HIF-la (Santa Cruz Biotechnology, sc-10790,
1:300), rabbit polyclonal anti-VEGF (Santa Cruz Biotechnology, sc-507,1:300).
Nitrocellulose membranes were incubated with secondary antibodies (Santa Cruz
Biotechnology) for 1 hour at room temperature. Immunoblots were then probed with an
ECL Plus chemiluminescence reagent kit (Amersham Biosciences, Arlington Heights,
IE) and visualized with the imagine system (Bio-Rad, Versa Doc, model 4000). The data
were analyzed by the software Quantity one 4.6.1 (Bio-Rad).
Brain Weight
Pups were euthanized and the brains were removed at 2 weeks after HI. The brain
was divided into the cerebral hemispheres, the cerebellum and brain stem, and weighed
on a high precision balance (sensitivity ± O.OOlg). Brain weight was expressed as the
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mass ratio of the ipsilateral hemisphere compared to the contralateral hemisphere
(Calvert et al. 2002).
Statistical Analysis
All the data were expressed as mean ± SEM. Statistical differences between more
than two groups were analyzed by using one-way ANOVA followed by Tukey post-hoc
analysis. Statistical difference between two groups was analyzed by using t-test. A P
value of <0.05 was considered statistically significant.
Results
HIF-la Inhibition Decreased Infarct Volume and Neuronal Cell
Death
2ME2 significantly decreased mean infarct volume in a dose-dependent manner at
higher dosages: 15 mg/kg dosage (18 ± 2%) and 150 mg/kg (10 ± 3%) as compared with
the vehicle-treated group (30 ± 1%), but not at the lower dosage: 1.5mg/kg (30 ± 1%)
(mean ± SEM, Figure 5A and 5B). Although, high dosage of 150 mg/kg showed maximal
decrease in infarct volume, it was accompanied with a high mortality (6 of 10 pups died)
(Figure 5B). All the other groups had zero mortality. 15 mg/kg was considered
appropriate dosage for rest of the experiments and for elucidating molecular mechanisms.
We tested the therapeutic time window by administering 2ME2 (15 mg/kg) at 5
min and at 3 h after HI. The infarct volume was significantly decreased by the 2ME2
treatment administered 5 min after HI (17 ± 2%) as compared with the HI group (30 ±
1%), but not by the treatment at 3 h after HI (28 ± 3%) (mean ± SEM, Figure 6A and 6B).
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Nissl staining of the coronal brain sections showed increased neuronal cell death
in the cortex and CAl and CA3 hippocampal regions of the ipsilateral hemisphere at 48 h
after HI. Neuronal cells, however, were substantially protected by 2ME2 treatment
(15mg/kg, administered 5 min after HI) (Figure 7).
HIF-1 a Inhibition Decreased BBS Disruption and Brain Edema
IgG staining was used to demonstrate BBB disruption as previously described
(Muramatsu et al. 1997), which led to IgG passing through the disrupted BBB and
penetrating into the brain parenchyma. IgG staining was performed at 24 h after injury.
The IgG-positive region in the HI group correlated well with the infarct area. The 2ME2-
treated group demonstrated a smaller IgG-stained region as compared with the HI group.
The DMOG-treated group showed an increase in the permeability of the BBB compared
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Figure 5. Effects of 2ME2 on the reduction of infarct volume.
(A) Representative TTC stained coronal brain sections from
sham, HI and treatment groups with different dosages of
2ME2 are shown. Number of animals, n = 10 for each group;
however, 6 pups died in the 150 mg/kg treated group. The
scale is shown On the left side of each TTC-stained brain with
1 mm being the shortest interval. (B) Quantitative analysis of
infarct volume revealed that 2ME2 treatment produced a
dose-dependent reduction in the infarct volume (*P<0.001,
versus HI and 1.5 mg/kg treatment; vertical bars indicate
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Figure 6. Therapeutic time window of 2ME2 treatment.
(A) Representative TTC stained coronal brain sections
from sham, HI and 2ME2 treated groups at different time
points (5 min or 3 h after HI). Number of animals, n = 10
for each group. The scale is shown on the left side of each
TTC-stained brain with 1 mm being the shortest interval.
(B) Quantitative analysis of infarct volume revealed that
2ME2 treatment has a therapeutic time-window; treatment
was effective when administered 5 min after injury whereas
it was ineffective at 3 h after injury (* P < 0.001, versus HI;



































Figure 7. Effects of 2ME2 on the reduction of neuronal cell death. Nissl staining of the
cortex and hippocampus region in coronal sections of the brain was performed for sham,
HI and HI+2ME2 groups at 48 h after insult. CAl and CA3 regions (shown by arrows
in uppermost panels) showed thiiming due to increased neuronal loss after HI. 2ME2
treatment ameliorated CAl and CA3 damage. In the cortex regions, less staining
density in HI group is due to more shruriken, pyknotic nuclei. These changes are
attenuated in HI+2ME2 group. The region of interest (ROl) for the higher
magnification is identified by boxes in low magnification images. The inset pictures
show highest magnification to show individual neurons. 2ME2 treatment prevented
neuronal cell death in the ipsilateral cortex and hippocampus after hypoxic-ischemic
injury. The scale represents 500 pm, 50 pm and 10 pm for low magnification, high
magnification and highest magnification respectively.
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Figure 8. IgG staining at 24 h after HI injury. IgG staining was performed in
sections of the rat brain of sham, HI and HI+2ME2 groups, respectively. There is
no staining in the sham section. A dense IgG staining (brown stain) was seen in
the ipsilateral cortex and hippocampus in both the HI group and HI+DMOG




























Figure 9. Brain water content at 48 h after HI injury. Quantification of brain
water content in the cerebellum, ipsilateral and contralateral brain hemisphere
48 h after HI. Compared with the sham and naive groups, the brain water
content was markedly increased in the HI group (*P < 0.001 vs. naive and
sham. The nai've group contained normal pups without any surgery or
treatment. Vertical bars indicate SEM). 2ME2-treatment significantly
decreased ipsilateral hemisphere water content (*P < 0.001 vs. HI), whereas
DMOG-treatment significantly increased its water content (# P < 0.05 vs. HI),
as compared with the HI group. There was no statistical difference among the
groups in contralateral hemisphere water content.
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Brain edema as indicated by increased brain water content was seen at 48 h after
HI. In the HI group, the water content in the ipsilateral hemispheres increased
significantly compared with the control (89.7 ± 1.35% vs. 87.2 ± 0.42%, P<0.001) and
sham groups (89.7 ± 1.35% vs. 87.0 ± 0.18%, P < 0.001). In the 2ME2-treated group, the
mean water content of the ipsilateral hemispheres differed significantly from HI group
(88.3 ± 0.99% vs. 89.7 ± 1.35%, P < 0.001). The DMOG-treated group had significant
more edema than the HI group (91.1±0.78% vs. 89.7 ± 1.35%). The contralateral
hemisphere and cerebellum did not show significant changes in brain water content
(Figure 9).
2ME2 Inhibits HlF-la and VEGF Expression
Immimohistochemical analysis of brain sections revealed that both HlF-la and
VEGF were extensively up-regulated in the cerebral cortex region of the ipsilateral
hemisphere at 24 h after HI, which was seen as brown granular deposits within cells.
After 2ME2 treatment, there were fewer cells with condensed staining of HlF-la and
VEGF (Figure lOA).
The immimohistochemical results were confirmed by Western blotting. Westem
blot analysis showed an upregulation of HIF-la 24 h after HI by about 2 fold (Figure
lOB), and it was significantly inhibited by 2ME2 (Figure lOB, P < 0.001, 2ME2 vs. HI,
ANOVA). VEGF was upregulated at 24 h after HI (Figure IOC, P < 0.001, HI vs. sham,
ANOVA) and it was significantly decreased in the 2ME2-treated group (Figure IOC). On
the other hand, in the DMOG-treated group, there was a significantly enhanced level of
HlF-1 protein compared with the HI only group (P < 0.05, vs. HI). Moreover, DMOG
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treatment elevated VEGF protein level and led to 2-fold increase compared with the HI
group (P < 0.001, vs. HI).
To further explore the relationship of HIF-la and VEGF expression with the
blood-brain-barrier disruption, we performed triple fluorescent staining in the cortex
region of the tissue for HIF-la, VEGF and the endothelial marker - von Willebrand
factor (vWF) - at 24 h after HI (Figure 11 A, low magnification; Figure 1 IB, high
magnification). The expression of HIF-la and VEGF were increased in the HI groups
compared with the sham group, which was also consistent with the results of the DAB
staining. Also, the upregulation of both proteins was observed in the vWF-stained cells.
A significant reduction in both neural and vascular HIF-la and VEGF expression was
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Figure 10. Immunohistochemistry and Western blot for HIF-la and VEGF expression
24 h after HI injury. (A) Inununostainihg for HIF-la and VEGF in the cortex of the
ipsilateral hemisphere at 24 h after HI. Compared with the HI group, HIF- la and VEGF
expression was reduced in the 2ME2 group. Arrowheads indicate cells that are positive
for HIF-la and VEGF. (B and C) Representative Western blot analysis showed that
HIF-la and VEGF (with 0-actin as a loading control) were expressed in the ipsilateral
hemisphere at 24 h after HI respectively. Quantification of the Western blot analysis
showed increased HIF-la and VEGF m the Hi group and DMOG-treatment group
compared with both the sham group and the 2ME2-treatment group (*P < 0.001, versus
sham; #P < 0.05, versus HI; vertical bars indicate SEM).
50
















Figure 11. Co-localization of HIP-la, VEGF in endothelial cells. HIF-la and VEGF
expression in endothelial cells and microvascular structures in the ipsilateral penumbra
cortex 24 h after HI injury. Triple immunofluorescence staining images are presented at
lower magnification (A, i-xii) and higher magnification (B, i-xii): HIF-la (red) (i,v,ix),
VEGF (green) (ii,vi,x), vWF (blue) (iii,vii,xi) and merged (iv,viii,xii). An increased
expression of HIF-la and VEGF were detected in the endothelial cells at 24 h after the
HI injury (v-viii) as compared to sham (i-iv). 2ME2 treatment reduced the expression of
HIF-la and VEGF (ix-xii). Arrows show vascular structures. Insets in the right comer of
v-xii are highest magnification showing endothelial structure and microvasculature. Scale
bar represents 200 pm for low magnification (A), 50 pm for high magnification (B) and
10 pm for the insets (highest magnification).
52
HH-2ME2ham H













□  Sham (n=5)
m  Hl(n~12)
^  HI + 2ME2(n=:11>
Figiure 12, Long tenn effects of 2ME2 treatment. (A) Top
view of the brain from sham, HI and 2ME2-treated-group
at 2 weeks after hypoxic-ischemic injury. There is a
significant tissue loss in the ipsilateral hemisphere in HI
group. In the 2ME2-treated group, tissue loss in ipsilateral
hemisphere was reduced. Nissl staining in coronal sections
of the brain were obtained at the same time. Extensive
cerebral and cortical atrophy and damage on the ipsilateral
hemisphere were seen in the Hi group which was
attenuated in the 2ME2-treated group. Arrowhead indicates
the atrophy. The quantification of the tissue loss (B) was
expressed as the mass ratio of ipsilateral/contralateral
hemisphere (*P < 0.001, versus sham; #P < 0.05, versus
HI; vertical bars indicate SEM.)
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Long-Term Effects of 2ME2 Treatment
There was significant loss of ipsilateral brain tissue in the HI groups at 2 weeks
post HI (Figure 12A). The tissue loss was attenuated in the 2ME2-treated animals.
V
Coronal sections were obtained at the level of CAl hippocampal region by 2 weeks after
HI and Nissl staining was performed. There was extensive cerebral atrophy and damage
on the ipsilateral side in HI group which was attenuated in the 2ME2-treated group
(Figure 12A).
To further quantify the tissue loss of the injury, pups were sacrificed at 2 weeks
after HI and the hemispheres were separated and weighed accurately. The mass ratio of
the ipsilateral/contralateral hemisphere demonstrated a significant reduction of 29.4% in
the HI group after injury compared to the sham group (0.7 ± 0.03 vs. 1.0 ± 0.04, P<0.05)
and presented an improvement of 20.1% in the 2ME2-treated rats (0.7 ± 0.03 vs. 0.9 ±
0.04, P<0.001) (Figure 12B).
Discussion
The present study showed for the first time that acute HIF-la inhibition provides
neuroprotection against hypoxic-ischemic brain injury in neonates. The neuroprotective
effects were associated with preservation of BBB with a subsequent reduction in brain
edema and attenuation of neuronal cell death.
2ME2 is a known HIF-la inhibitor currently being evaluated in different clinical
trials for cancer patients (Sweeney et al. 2005;Dahut et al. 2006;James et al. 2007).
During phase I clinical trial in patients with solid tumors, 2ME2 was administered at
400mg - 3000mg b.i.d for consecutive 28 days (Dahut et al. 2006). The 2ME2 dosages in
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our study were based on previous studies by others that have shown effective HIF-la
inhibition at dosage of 5 mg/kg with neuroprotection in adult rat models (Yan et al. 2006;
Chen et al. 2007). Mabjeesh et al. showed an effective inhibition of angiogenesis with
high dose 2ME2 (150 mg/kg) (Mabjeesh et al. 2003). To evaluate the effectiveness of
entire spectrum of 2ME2 dosages (low-high), we administered 1.5,15 and 150 mg/kg
of 2ME2. Our results indicated that HIF-la inhibition using 2ME2 provided
neuroprotection in a dose-dependent manner by attenuating infarct volume after neonatal
HI. The optimum dosage of 15 mg/kg, indicated by significant reduction in infarct size
without accompanying morbidity or mortality is comparable to previous experimental
studies in adult rat models (Chen et al. 2007; Yan et al. 2006). The lowest dose -1.5
mg/kg did not show significant attenuation of infarct volume which is likely due to
ineffective inhibition of HIF-la. But, this needs to be further clarified. On the other hand,
the exact cause of high mortality observed in the high dose - 150 mg/kg group is not
known. However, adverse effects of 2ME2 such as fatigue, diarrhea, anorexia, nausea
and hepatic toxicity have been reported in the past in clinical studies (Sweeney et al.
2005; Dahut et al. 2006).
HIF-la induction has a different temporal profile depending on the type of brain
injxuy as well as age in experimental models. Our previous studies as well as others have
shown that HIF-la protein levels increased and peaked at 3-4 hr after hypoxic-ischemic
injury (Calvert et al. 2006;van den Tweel et al. 2006), at 7.5 hrs after focal cerebral
ischemia in adults and at 96 hrs in adult global ischemic model (Jin et al. 2000; Li et al.
2005a). The ineffectiveness of 2ME2 when administered at 3 h after HI in the present
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study strongly suggested that neuroprotective effects are dependent on early HIF-la
inhibition i.e. before peak levels.
Early pathological sequelae such as increased vascular permeability and brain edema
formation are known to be triggered within hours after cerebral ischemic injuries (Zhang
et al. 2000). VEGF, an important HIF-la target gene is known to play a critical role in
the early phase after different forms of brain injury by causing BBB disruption leading to
cerebral edema (Fagan et al. 2004;Nag et al. 1997;Zhang et al. 2000; Jadhav et al. 2007).
Previous studies have suggested that VEGF induces BBB leakage by releasing nitric
oxide (Wu et al. 1996), alteration of delocalization and expression of tight junction
proteins such as zonula occludens-l(ZO-l) (Fischer et al. 2002), VEGF receptor
induction (Zhang et al. 2000), and activation of vesicular-vacuolar organelles in the
cytoplasm of endothelial cells (Feng et al. 1996). Our results indicated that acute HIF-la
inhibition with 2ME2 decreased the HIF-la and VEGF protein levels, which were
significantly increased after HI. Triple fluorescent staining showed that HIF-la and
VEGF were colocalized in the endothelial cells and upregulated after HI. Others have
shown similar findings of HIF-la and VEGF upregulation in neuronal tissue after
neonatal brain injury (Mu et al. 2003;Kaur et al. 2006). It has been previously suggested
that the inhibition of VEGF at the acute stage of stroke may be beneficial (Fagan et al.
2004;Zhang et al. 2000). Our data showed that 15 mg/kg dose of 2ME2 attenuated the
BBB disruption as well as the ensuing brain edema after HI. The results from our study
taken together with published studies suggested that early inhibition of HIF-la is
associated with decrease in VEGF levels and protection of BBB with reduction of brain
edema. Further interpretation of the data suggested that HlF-la and VEGF in the vascular
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endothelium of the intraparenchymal vessels may be critieal in the BBB disruption after
neonatal brain injury. Whether, HIF-la and VEGF from astrocytes (Ishikawa et al.
2007;Zhang et al. 2006) and neurons (Halterman et al. 1999) contribute to BBB
permeability and brain edema formation needs to be clarified in future studies.
However, in addition to VEGF, other factors may also contribute to increased
vascular permeability and tissue damage after bypoxic-iscbemie insult, such as nitric
oxide (Mayban 1999) and TGF-P (Lu et al. 2006). HIF-la regulates a multitude of genes
involved in glycolysis, inflammation, apoptosis, and proteolysis. It is possible that VEGF
down-regulation by acute HIF-la inhibition in this study is only one of the
neuroprotective mechanisms that ameliorate BBB destruction and brain damage.
It is possible that the neuroproteetion imparted by 2ME2 in this study is via
multiple pathways independent of VEGF. 2ME2 mediated HIF-la inhibition has been
shown to be anti-apoptotie via BNIP3 pathway (Yan et al. 2006;Cben et al. 2007).
Neuroproteetion by HIF-la inhibition could also act via p53 and /or caspase-3 pathway
as reported earlier (Halterman et al. 1999;Van Hoeeke et al. 2007) It is suggested that
there is a causative relationship between HIF-la and caspase-3 induction through HIF-la
functional binding to the caspase-3 gene promoter (Van Hoeeke et al. 2007). These HIF-
la dependent pathways could be involved in protection of neurons by 2ME2 in this study.
It can be debated whether 2ME2 effects are entirely mediated via HIF-la
inhibition. Besides down-regulating HIF-la, other properties of 2ME2 have been
reported, such as antiproliferative, anti-angiogenie, antitumorigenic, anti-
neovaseularization (Mabjeesb et al. 2003;Klauber et al. 1997;Pribluda et al. 2000), and
alteration of inflammatory response (Cbauban and Anderson 2003). However, recently
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published in-vitro as well as in-vivo reports have provided evidence that 2ME2 is an
effective HIF-la blocker. Mabjeesh et al reported that 2ME2 has a direct effect on HIF-
la inhibition and not as a result of a "side effect" of mitotic arrest. 2ME2 was specific for
the HIF-la subunit, and had no effect on HIF-IB or other transcription factors such as c-
fos, c-jun (Mabjeesh et al., 2003). In vitro studies demonstrated that 2ME2 treatment
reduced the levels of nuclear and total HIF-la protein in a dose dependent manner
(Mabjeesh et al., 2003). Chen et al recently demonstrated in focal ischemia model that
2ME2 inhibition of HIF-la did not occur at the transcriptional level, but via translational-
dependent pathway (Chen et al., 2007).
To ascertain whether 2ME2 neuroprotective effects are indeed mediated via HIF-
la inhibition, and to ascertain the critical role of HIF-la in neonatal hypoxic-ischemic
injury, we used DMOG, a knovra HIF-la activator with guidance fiom previously
published reports (Milkiewicz et al. 2004). DMOG is a cell penetrant oxoglutarate
analogue known to stabilize HIF-la by inhibiting prolyl hydroxylase domain enzymes
(PHD) 1-3 and asparaginyl hydroxylase activity (FIH, factor inhibiting HIF) (Jaakkola et
al. 2001). PHDs are an important cellular mechanism regulating the HIF pathway
resulting in von Hippel-Lindau complex-mediated ubiquity lation of HIF-la and
consequent degradation by the proteasome. In our study, DMOG increased HIF-la
protein levels by 1.5 times and VEGF protein levels by almost 2 times as compared to HI
alone. Moreover, the DMOG treated animals also showed qualitatively more BBB
disruption and significantly higher brain edema than HI group. This evidence indicated
an important role for HIF-la in neonatal brain injury.
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HIF-la inhibition was seen to be protective after neonatal HI in acute settings; the
present study also showed that acute HIF-la inhibition provided long-term
neuroprotection. The severe tissue loss and brain atrophy observed 2 weeks after HI,
similar to previous reports (Calvert et ah, 2002) were significantly reduced in the 2ME2-
treated group. Neuronal protection was also observed at 48 h after HI. Thus, it is likely
that the long-term neuroprotection by HIF-la inhibition was dependent on early events
such as reduction in infarct size and attenuation of neuronal cell death.
Conflicting reports have raised debates on the exact role of HIF-la after cerebral
ischemia (Baranova et al. 2007;Bergeron et al. 2000;Sharp et al. 2004;Halterman et al.
1999;Goda et al. 2003;Aminova et al. 2005;Carmeliet et al. 1998). Previous literature
clearly indicated that preconditioning induced by various stimuli such as hypoxia,
deferoxamine, and cobalt chloride upregulated HIF-la that imparts neuroprotection
(Jones et al. 2006b;Sharp et al. 2004;Hamrick et al. 2005;Stenzel-Poore et al. 2003) after
cerebral ischemia. However, recent experimental in-vivo studies have shown that
neuroprotective agents administered as post-treatment can provide neuroprotection
against adult brain ischemic injuries with a concurrent decrease in HIF-la, suggesting
that HIF-la inhibition is beneficial (Chang et al. 2007;Chen et al. 2007). It is thought that
HIF-la upregulation after hypoxic preconditioning provided neuroprotection, however,
in the absence of preconditioning the post ischemic HIF-la increase actually promoted
cell death (Chang and Huang 2006). On the other hand Li et al. (Li et al. 2005a) recently
suggested that HIF-la may play an anti-apoptotic role after neonatal hypoxia-ischemia.
However, their conclusion was based on comparison between hypoxic insult (relatively
mild stimulus) and hypoxic-ischemic insult (severe stimulus) without pharmacological
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manipulations. Recently Baranova et al. reported that HIF-la mediated beneficial
responses overall using neuron-specific knockdown HIF-la mice in focal ischemia model.
However, this study examined permanent inhibition (knockdown) of HIF-la inhibition in
the mutant mice, whereas we acutely inhibited the initial surge of HIF-la after brain
injury. Interestingly, Baranova et al. reported there are two phases of HIF-la activation
after cerebral ischemia. The first phase occurred immediately after injury till 12 h, which
correlated with the upregulation of various HIF-1 target genes, including most pro-death
genes. However, in the second phase of HIF-la activation, which lasted up to 10 d, pro-
death genes such as BNIP3, Nix etc., remained rmchanged (Baranova et al., 2007). It
further supported our data by suggesting that HIF-la may contribute to cell death during
the acute phase after ischemia.
The role of HIF-la in mediating prodeath or prosurvival responses is likely
dependent on the duration of the stimulus (Halterman and Federoff 1999), the types of
pathological stimuli (Aminova et al. 2005), and the cell type that it is induced in
(Vangeison et al. 2008). Recent work by Vangeison et al. suggests that selective loss of
HIF-la function in astrocyte cultures provides neuroprotection from hypoxia, whereas
loss of neuronal HIF-la increases neuronal susceptibility to hypoxia-induced damage. It
suggests that the pathological functions of HIF-la could be cell type specific. The
possible differential roles of HIF-1 in different cell types may provide partial
explanations for the divergent results from different groups. In our study, as well as the
study by Helton et al. (Helton et al., 2005), HIF-Ia inhibition involved neuronal as well
as non-neuronal cell types in the CNS, which may result in an overall pathological role
for HIF-Ia. Therefore, it is possible that the benefits of blocking HIF-Ia across non-
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nenronal cell types outweigh the potential negative side effects of neuron specific HIF-la
blockade.
Thus, HIF-la inhibition with pharmacological agents such as 2ME2, especially in
the early stages after ischemic brain injury as shown in the present study provides
promise as therapeutic strategies. The present study also showed that early HIF-la
inhibition can provide long-term neuroprotection. In summary, the present study
indicated that acute HIF-la inhibition early after injury provides neuroprotection by
preserving BBB integrity, ameliorating brain edema, attenuating neuronal injury and
reducing infarct volume after neonatal hypoxic-ischemic brain injiuy.
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Abstract
The present study was designed to investigate the role of MMPs in the immature
brain and the long term effects of early MMPs inhibition after hypoxic-ischemic (HI)
injury.
HI was induced by imilateral ligation of the right carotid artery followed by
hypoxia (8% O2 for 2 h) in P7 rat pups. GM6001, a broad spectrum MMPs inhibitor, was
injected (50 mg/kg or 100 mg/kg) intraperitoneally at 2 h and 24 h after HI injury. BBB
integrity, brain edema, MMP-2/-9 activity, TIMP-1/-2 and tight junction protein (TIP)
level were evaluated using IgG staining, Evan's blue extravasation, brain water content,
zymography and Western blot. Doxycydine, another MMPs inhibitor, was injected (10
mg/kg or 30 mg/kg) intraperitoneally at 2 h after HI, then BBB integrity and brain edema
were measured at 48 h post-HI using brain water content measurement and IgG staining.
The long-term effects of early MMPs inhibition (GM6001,100 mg/kg) were evaluated by
neurobehavioral tests, body weight, and brain atrophy measurement.
GM6001 attenuated brain edema and BBB disruption at the dosage of 100 mg/kg.
MMP-2 activity increased at 24 h and peaked at 48 h after HI, whereas MMP-9 activity
peaked at 24 h and tapered by 48 h after HI. MMP-9/-2 activities were significantly
attenuated by GM6001 at 24 h and 48 h after HI. The degradation of TJPs (ZO-1 and
occludin) at 48 h after HI was reversed by GM6001 treatment. Early MMPs inhibition
had long-term effects that attenuated ipsilateral brain tissue loss, and improved
neurobehavioral outcomes after HI. These results suggest that early MMPs inhibition
with a broad-spectrum inhibitor provides both acute and long-term neuroprotection in the
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developing brain by reducing TJPs degradation, preserving BBB integrity, and
ameliorating brain edema after neonatal HI injiuy.
Introduction
Matrix Metalloproteinases (MMPs) are zinc-dependent endopeptidases which are
capable of degrading many types of extracellular matrix proteins and involved in the
process of tissue remodeling in various pathologic conditions, including inflammatory
diseases, tumor cell invasion, and angiogenesis. Previous studies suggest that MMPs, in
particular MMP-2 and MMP-9, are deleterious in the brain after stroke (Power et al.
2003; Svedin et al. 2007). In acute stage after ischemic stroke, the effect of MMP activity
is correlated to degradation of neurovascular matrix and opening of blood-brain barrier,
which promotes vasogenic edema and results in neurological deficits. However, recent
studies suggest that MMPs were also indicated to be involved in the repairing phase in
the delayed stage after cerebral ischemia, including neuroblasts migration and neuronal
plasticity (Lee et al. 2006; Zhao et al. 2006).
Perinatal hypoxic-ischemic (HI) brain injury is the major cause of morbidity and
mortality to infants and children, with an incidence of 2-9 per 1000 babies (Vannucci
1990). In the newborn infants who exhibit hypoxic-ischemic encephalopathy, 20% to
50% of which expire during the newborn period and up to 25% of which develop
permanent neurological deficits (Vannucci et al. 1999). Compared with the adult brain,
the neonatal brain that is in the developing stage is different in physiological structure,
function, cellular composition and signaling pathways related gene activation and protein
expression. Not only pathophysiological process, the MMPs also participate in many
normal biological processes, such as embryonic development, organ morphogenesis,
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blastocyst implantation, bone remodeling and woimd healing (Brew et al. 2000). Due to
the dual role of MMPs in the hrain and their importance to the normal brain development,
it is interesting to discover the role of MMPs in the developing brain after neonatal HI
and, more importantly, its long-term effects on the neurological function.
Materials and Methods
The animal protocol of this study has been approved by The Institutional Animal
Care and Use Committee (lUCAC) at Loma Linda University. Timed pregnant female
Sprague-Dawley rats were obtained from Harlan Laboratories, Indianapolis, IN, and
housed in individual cages. The rats were under a 12;12-h light-dark cycle, with food and
water available ad libitum throughout the study.
I
Hypoxic-Ischemic Insult
A modified Rice-Vannucci model (Rice, III et al. 1981) was used as previously
described (Chen et al. 2008). Briefly, 7-day-old (day of hirth = day 0) postnatal pups
were anesthetized with 3% isoflurane. The right common carotid artery of each pup was
identified, exposed, and permanently ligated with 5-0 surgical silk through a near-midline
incision. After recovering in their dams for 2 hours, the pups were then placed in ajar
perfused with 8% oxygen (balanced with nitrogen) at 4L/min for 2 h. A constant
temperature of 37°C was maintained throughout all the procedures. After hypoxia, the
animals returned to their dams and the ambient temperature was maintained at 37°C for
24 h. Sham animals underwent anesthesia and the common carotid artery was exposed
without ligation and hypoxia.
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Drug Administration
GM6001 (Chemicon, CA) is a broad-spectrum MMP inhibitor and was prepared
followed as others described with modification (Yamamoto and Nguyen 2006). GM6001
was dissolved in dimethyl sulfoxide (DMSO) as a stock solution and further
supplemented in 0.01% polyoxyethylenesorhitan monooleate (Tween 80) in O.OIM PBS
to a total volume of 200 pi immediately before administration (final concentration of
DMSO = 2%). GM6001 (50 mg/kg or 100 mg/kg) or vehicle (200 pi, 2% DMSO, 0.01%
Tween, O.OIM PBS) was administered intraperitoneally at 2 h and 24 h after HI. Animals
that were sacrificed before 24 h post HI (including 24 h) received only one dose
treatment.
Doxycycline has been shown to inhibit MMPs activity (Burggraf et al. 2007).
Doxycydine (Sigma, St. Louis, MO) was dissolved in O.OIM PBS as a final volume of
200 pi and was administered intraperitoneally at lOmg/kg or 30mg/kg as a one-time dose
at 2h post HI (Jantzie et al. 2005;Burggraf et al. 2007). All the doxycycline was prepared
fresh and protected from light.
Experimental Groups
Pups were randomly assigned to one of the following groups: sham,
sham+GM6001 (100 mg/kg), hypoxia-ischemia (HI), HI + low dose GM6001 treatment
(HI+GM6001-50, 50mg/kg), HI + high dose GM6001 treatment (HI+GM6001-100,
lOOmg/kg), HI + low dose doxycycline treatment (HI+Doxy-lO, 10 mg/kg), and HI +
high dose doxycycline treatment (HI+Doxy-SO, 30 rrig/kg).
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Brain Water Content
At 48 h after HI, animals were deeply anesthetized and the brains were removed
and divided into three parts (right hemisphere, left hemisphere, and cerebellum) for water
content measurement. Each part was weighed on a high precision balance (Denver
Instrument, sensitivity ± 0.001 g) immediately after removal (wet weight) and again after
drying in an oven at 105°C for 24 hours as previously described (Chen et al. 2008). The
percentage of water content was calculated as [(wet weight-dry weight) / wet weight] x
100%.
Gelatin Zymography
MMP-2/-9 activity was measured by gelatin zymography as previously described
(Tsubokawa et al. 2006) with modification. The ipsilateral hemispheres were
homogenized by lysis buffer (50 mmol/L Tris-HCl, pH7.4, 150mmol/L NaCl, 1% Nonide
P-40, 0.1% SDS, 0.1% deoxycholie acid) with protease inhibitor cocktail (Sigma, MO,
USA). Samples were further centriftiged at 14,000g at 4°C for 20 min and the
supematants were collected. The protein concentration of the supernatant was measured
using DC protein assay (Bio-Rad, CA, USA) and equal amormts of samples were
electrophoretically separated on 10% zymogram gels (Bio-Rad, CA, USA). Gels were
washed in renaturation buffer (Bio-Rad, CA, USA) for Ih and then incubated at 37°C for
48h with a developing buffer containing 50 mmol/L Tris, pH 7.6, 5 mmol.L CaCL, 200
mmol/L NaCl, and 0.2% (w/v) Brij-35. After development, the gels were stained with
0.5% Coomassie blue R-250 for Ih and then destained until clear bands appeared on a
blue backgrormd. Human MMP-9/-2 (Chemicon, CA, USA) was used as gelatinase
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standards. Gel pictures were taken and MMP-2/-9 activity was quantified with Image J,
version 1.32.
Blood-Brain Barrier Permeability Measured by Evan's Blue and IgG
Staining
At 48 h after HI injury, Blood-Brain Barrier disruption was visualized by IgG staining
and quantified using Evans blue extravasation as previous report (Belayev et al.
1998;Tsubokawa et al. 2006). Brain slides from four groups (sham, HI, HI+GM6001-100,
HI+Doxy-30) were used for IgG staining, which goat anti-rat IgG-biotin conjugated
(Santa Cruz Biotechnology, CA, USA) and ABC staining kit was used (Santa Cruz
Biotechnology, CA, USA). Samples from three groups (Sham, HI, HI+GM6001-100)
were used for Evans blue dye extravasation. Briefly, Evans blue dye (2% in saline, 4
ml/kg) was injected intravenously via jugular vein at 47h after HI and was allowed to
circulate for Ih. Then the animals were perfiised with PBS until colorless fluid was
appeared from the right atrium. After decapitation, the brains were divided into left and
right hemisphere and rapidly frozen at -80C. The tissue was weighed and placed in 50%
trichloroacetic acid following homogenization and centrifugation. The amount of
extravasated dye in die brain was determined by spectroflurophotometry with an
excitation wavelength of 610 nm. The data are expressed as amovmt of Evan's blue dye
per brain tissue mass (ng / mg brain tissue).
Immunohistochemistry
Animals were deep anesthetized and sacrificed at 24h after HI, perfusing with
cold 0.1 M PBS followed by 4% paraformaldehyde. Brains were postfixed overnight.
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dehydrated in 30% sucrose in 0.1 M PBS and left at 4°C till the brains sunk. Coronal
sections of lOpm thick were cut using the cryostat (CM3050S, Leica Microsystems) as
described (Yin et al. 2003). For fluorescence immunohistochemistry, after blocking with
donkey serum, brain sections were incubated with primary antibody overnight at 4°C,
which were individually GFAP (Chemicon, CA, USA), von Willebrand Factor (vWF,
Chemicon, CA, USA), MMP-9 (Chemicon, CA, USA). After rinsing with PBS, the
sections were incubated for 1 hr in fluorescein isothiocyanate (FITC)-, Texas red-
conjugated secondary antibodies (Jackson Immunoresearch, PA; 1:100). The sections
were then visualized using a fluorescent microscope (Olympus BX51, Olympus Optical
Co. Ltd, Japan) and pictures were taken (MagnaFire SP 2.IB software).
Western Blotting
Animals were sacrificed at 3 h, 12 h, 24 h, and 48 h after HI (n = 6 for each group) for
Western blot analysis as described by previous report (Ostrowski et al. 2005;Tsubokawa
et al. 2006). After perfused by cold PBS, the brains were removed and was homogenized
by lysis buffer (50 mmol/L Tris-HCl, pH7.4,150mmol/L NaCl, 1% Nonide P-40, 0.1%
I
SDS, 0.1% deoxycholic acid) with protease inhibitor cocktail (Sigma, MO). Samples
were further centrifuged at 14,000g at 4°C for 20 min and the supematants were collected.
Protein concentration was measured using DC protein assay (Bio-Rad, CA). Equal
amounts of protein (50 pg) were loaded on a sodium dodecyl sulfate (SDS)
polyacrylamide gels. After electrophoresis, proteins ftom gels were transferred to
nitrocellulose membranes and then blocked with 5% non-fat milk in TBS. Membranes
were incubated overnight at 4°C with primary antibodies, which are zonula occludens-1
(ZO-1, Invitrogen, CA), occludin (Santa Cruz Biotechnology, CA), MMP-2 (Santa Cruz
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Biotechnology, CA), MMP-9 (Chemicon, CA), tissue inhibitors of MMP (TIMP) -1
(Chemicon, CA), and TIMP-2 (Chemicon, CA). Membranes were then incubated with
secondary antibody (Santa Cruz Biotechnology, CA) for Ih at room temperature.
Immunoblots were then probed with an ECL Plus ehemiluminescence reagent kit
(Amersham Bioscienees, IL, USA) followed by exposure to X-ray films. Films were
seanned and the proteins were quantified by bands densitometry using Image J (NIH)
software.
Body Weight and Brain Atrophy
Body weight of rat pups was monitored for 2 weeks after HI injury as an indicator
of their general health. Pups were euthanized and the brains were removed at 2 weeks
post HI. The ipsilateral and eontralateral hemisphere were separated by a midline incision
and then weighed on a high precision balance (sensitivity ± 0.00 Ig). The data was
expressed as the brain hemisphere tissue mass.
Neurobehavioral Testing
Locomotor Activity
Open field test measures the activity and habituation response of animals in a
novel environment (Fan et al. 2005). Pups were plaeed in the ehambers in a quiet room
with dimmed light and the movements were recorded during a 30-min testing period by
using the Video Traeking System SMART-2000 (San Diego Instruments Ine., CA). The
test was performed from age of 12-day-old to 20-day-old daily. The total distanee,
moving speed and % moving time were traeked and calculated by a computer (Polytrack,
San Diego Instruments, San Diego, CA).
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Cylinder Test
Sensorimotor function was evaluated by cylinder test (Chang et al. 2005; Schallert et
al. 2000) which is a test of limb use asymmetry for animals with a imilateral lesion.
Briefly, the rats were individually placed into a transparent cylinder with 20 cm in
diameter and 30 cm in height and the forelimb usage will be recorded for 5 minutes. The
ipsilateral (right) or contralateral (left) forepaw contacts, or simultaneous both forepaws
contacts with the wall of the cylinder were counted, and were calculated as the
percentage of total forepaw contacts. All scoring was done by the person who was blind
to group assignment.
Morris Water Maze Test
Water maze test was performed at 7 weeks after HI injury as previous described
(Hartman et al. 2006), which is used to assess the ability to leam spatial locations and
memory. Briefly, this test requires the rats to find a visualized or hidden (submerged)
platform in a pool of water using visual cues in the room. The water maze consisted of a
pool (118 cm diameter) filled with water made opaque by the addition of white non-toxic
tempera paint. The pool contained a platform (22 cm diameter) that rats could step on to
escape the water. The platform location and entry point were varied according to a preset
scheme. All trials last a maximum of 60 s, at which point the rats were manually guided
to be placed on the platform. All the activities were recorded and the animals' swimming
f
paths were measured for quantification of, swimming latency by the Video Tracking
System SMART-2000 (San Diego Instruments Inc., CA).
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Statistical Analysis
Data are presented as mean ± SEM. Statistical differences between more than two
groups were analyzed by using one-way ANOVA followed by Turkey multiple
comparison procedure. Significance differences between two groups were analyzed using
t-test (SigmaStat, 3.1). Water maze data were analyzed using the general linear models
repeated measures ANOVA (Statistica 6.0). P value below 0.05 was considered as
statistically significant.
Results
MMPs Inhibition Decreased BBB Disruption and Brain Edema at
48 h after HI Injury
In neonatal HI model, the combination of hypoxia and ischemia results in a
spectrum of brain damage primarily in the territory of the middle cerebral artery of the
ipsilateral cerebral hemisphere. The brown IgG-positive stain demonstrated BBB leakage
in the frontal cortex and basal ganglia area after HI (Figure 13). Less extent of IgG-
positive stain was observed in either GM6001-100mg/kg or doxycycline-30mg/kg treated
group, especially in the frontal cortex region (Figure 13).
Quantitative result for BBB disruption was obtained by Evan's blue extravasations.
The Evan's blue dye concentration (ng / mg brain tissue) in the ipsilateral hemisphere for
the sham, HI, and HH-GM6001-100mg/kg groups was 1.35 ± 0.16, 2.64 ± 0.21, and 2.03
±0.10, respectively (Figure 14). There was a significant increase in the HI group
compared to the sham group (#P < 0.01, HI vs. Sham, ANOVA). Treatment with
lOOmg/kg GM6001 significantly reduced the BBB opening on the ischemic side (*P =
72
0.043, HI+GM6001-100mg/kg vs. HI, ANOVA). In the contralateral hemisphere, there is
no significant difference in all the groups.
Brain edema formation was observed at 48 h post-HI. The water content of the
ipsilateral hemispheres in the HI group was significantly increased compared with the
sham group (90.5±0.2% vs. 86.9±0.2%, P < 0.001, ANOVA, Figure 15). Brain water
content was significantly reduced only by high-dose regimen of GM6001 treatment. The
mean water content of the ipsilateral hemispheres in 100 mg/kg GM6001 treated-group
was 89.3+0.3% (*P = 0.029, vs. HI group, ANOVA, Figure 15). For low-dose Doxy
treatment (10 mg/kg), the water content in the ipsilateral hemisphere was not
significantly different (HI vs. HH-Doxy, 90.5+0.2% vs. 90.6+0.1%, P > 0.05, ANOVA).
However, in the high-dose Doxy treated group (30 mg/kg), the mean water content in the
ipsilateral hemisphere was reduced to 89.2+0.3% and it was significantly different
compared with the HI group (*P = 0.019, ANOVA, Figure 15). No statistical difference






Figure 13. IgG staining at 48 h after HI injury. IgG staining was performed in
sections of the rat brain of sham, HI, HH-GMhOOl -lOOmg/kg, and HI+Doxy-
3 Omg/kg groups, respectively. There is no staining in the sham section. A dense
IgG staining (brown stain) was seen in the ipsilateral cortex and hippocampus in
the HI group. After MMPs inhibition by GM6G01 or doxycycline, BBB























Figure 14, Evans blue dye extrayasation at 48 h after HI
injury. Evan's blue dye in ipsilateral brain hemisphere was
quantified at 48 h after HI. The data are expressed as amount
of Evan's blue dye per brain tissue mass. In the ipsilateral
hemisphere, the amount of Evan's blue dye significantly
increased 48 h post-HI (#P <0.01 vs. sham, ANOVA).
GM600I treatment reduced the Evan's blue dye leakage
compared with HI group C"? = 0.043 vs. Hi, ANOVA). In
the contralateral hemisphere, there is no significant
difference in all the groups. All vertical bars indicate SEM. N




























Figure 15. Effects of MMPs inhibition on brain edema at 48 b after HI. Brain water
content was quantified in the ipsilateral, contralateral brain bemispbere and cerebellum at
48 b post-HI. The brain water content was significantly increased in the HI group
compared with the sbam group (#P < 0.001 vs. sbam, ANOVA). GM6001 treatment at
100 mg/kg dosage, or doxycycline treatment at 30 mg/kg dosage, significantly decreased
ipsilateral bemispbere water content (*P < 0.05 vs. HI, ANOVA). There was no statistical
difference among the groups in contralateral bemispbere or cerebellum water content. All
vertical bars indicate SEM. N = 5 animals for sbam group. N = 10 animals for HI group.
N = 6 animals for HI+GM6001-50 mg/kg group. N = 7 animals for HI+GM6001-100
mg/kg group. N = 8 animals for HI+Doxy-10 mg/kg. N = 7 animals for HI+Doxy-SO
mg/kg.
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Temporal Profile of MMP-2 / 9 Activities after Neonatal HI Injury
To explore the temporal profile of MMP-2/-9 activation after HI injury, and confirm
the MMPs inhibition by GM6001 at the dosage of 100 mg/kg, pups (n=6 per time point)
were sacrificed at 3 h, 12 h, 24 h, and 48 h post HI and gelatin zymography assay was
performed. MMP-9 activation peaked at 12 h - 24 h post-HI with about 4.5 fold higher
than the base level (Figure 16A, #P < 0.05 vs. sham, ANOVA). Meanwhile, MMP-2
activation was later than MMP-9 activation and it peaked at 48 h post-HI with about 3
fold higher than the base level (Figure 16B, #P < 0.05 vs. sham, ANOVA). Our results
showed that GM6001 treatment (100 mg/kg) blocked MMP-9 activation at 24 h post HI
and inhibited MMP-2 activation at 24 h and 48 h post HI.
The Expression of MM-2 /-9 and TIMP-11-2
Western blots data indicate that active MMP-9 (act-MMP-9) level peaked at 24 h and
declined at 48 h after HI, while active MMP-2 (act-MMP-2) level peaked at 48 h post-HI
(Figure 17, A-C). Meanwhile, TIMP-1 expression showed a significant elevation at 48 h
post-HI by about 2 fold (Figure 17B, *P < 0.05, HI-48h vs. sham, ANOVA), which was a
delayed and lower level of increase compared with the elevation of act-MMP-9. TIMP-2
expression was also increased at 48 h post-HI by about 3 fold (Figure 17C, *P < 0.05, HI-
48h vs. sham, ANOVA), which was corresponding to the temporal profile and level of
act-MMP-2 activation. Both TIMP-1 and TIMP-2 expression were significantly reduced























Figure 16. Temporal profile of MMP-2/-9 activities following HI injury. MMP-2/-9
activities were measured at 3h, 12h, 24h and 48h after HI injury. Gelatin zymography
showed that after neonatal HI injury, MMP-2/-9 activity progressively increased over
24 h (#P < 0.05 vs. sham, ANOVA). GM6001 treatment significantly inhibited MMP-9
activity at 24 h post-HI, and inhibited MMP-2 activity at 48 h post-HI (For MMP-9, *P
< 0.05 vs HI-24h; for MMP-2, $P < 0.05 vs. HI-48h; ANOVA, vertical bars indicate
SEM). MMP-2/-9 standards are loaded as positive controls (Chemicon, CA, USA). N =
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Figure 17. HI activates MMP-2/-9 and promotes TIMP-1/-2 expression. (A)
Representative Western blots for MMP-2/-9 and TIMP-1/-2 from ipsilateral hemisphere
at 3 h, 12 h, 24 h and 48 h post-HI is shown (with P-actin as a loading control).
Quantification of the Western blot analysis showed the levels of act-MMP-2/-9 and
TIMP-1/-2 were increased following HI injury progressively (Figure 17B, for act-MMP-9,
#P < 0.05 vs. sham; for TIMP-1, *P < 0.05 vs. sham; $P < 0.05 vs. HI-48h; Figure 17C,
for act-MMP-2, #P < 0.05 vs. sham; for TIMP-2, *P < 0.05 vs. sham; $P < 0.05 vs. HI-
48h;ANOVA, vertical bars indicate SEM). N = 6 animals for each group.
3.4 Cellular Distributions of MMP-9 at 24 h after HI Injury
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Since endothelial cells and the end-foot of astrocytes are the major structural
components of BBB, to confirm the cell-types and sources of MMP-9 expression, double
staining for GFAP/MMP-9 and vWF/MMP-9 were performed on the brain sections at 24
h after HI injury. Double-staining result showed that the MMP-9 expression was co-
localized with both astrocytes (Figure 18 A) and endothelial cells (Figure 18B), which
was observed in the frontal cortex area. It suggests MMP-9 activation may have highly
association with BBB disruption.
MMPs Inhibition Preserved the Degradation of TJPs 48 h following HI
Injury
We studied two major proteins involved in the tight junctions of BBB, ZO-1 and
occludin. ZO-1 is a peripheral membrane protein which is localized along blood vessels
to form BBB in the brain parenchyma. It is an indicator for the presence of tight junctions.
Occludin is another important TIP which interacts with ZO-1 and links the tight junction
to the cytoskeleton. Our data showed that both ZO-1 and occludin were significantly
degraded in the ipsilateral hemisphere starting at 12 h reoxygenation following neonatal
HI (Figure 19A and 19B, #P < 0.001). However, loss of ZO-1 and occludin protein were
successfully reversed after MMPs inhibition (Figure 19A and 19B, *P < 0.001 vs. HI-12h,
HI-24h, and HI-48h).
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Figure 18. Cellular Distributions of MMP-9. At 24 h after HI, double fluorescent labeling
for MMP-9 with GFAP (A, i-ix, arrowheads indicate astrocyt^s and cells that are positive
for MMP-9) and MMP-9 with vWF (B, i-ix, arrowheads indicate endothelial cells and
cells that are positive for MMP-9) in the cortex of the ipsilateral hemisphere is shown
(Scale bar represents 100 pm). MMP-9 activation is shown in the HI group, and it is co-
localized with both astrocytes and endothelial cells (A, ix and B, ix, as indicated by



































Figure 19. Tight junction proteins expression. MMPs inhibition preserved the degradation
of TJPs at 48 h post HI. Representative Western blots for ZO-1 and oeeludin at 3h, 12h,
24h and 48h post-HI is shown (with p-aetin as a loading control). Both ZO-1 and
oeeludin in the ipsilateral hemisphere are reduced progressively followed by HI injury
(For ZO-1, #P < 0.05 vs. sham, ANOVA; for occludin, #P < 0.05 vs. sham, ANOVA).
GM6001 treatment significantly reversed the reduction of ZO-1 and occludin at 48 h
post-HI (For ZO-1, *P < 0.05 vs. HI-12h, HI-24h, and HI-48h, ANOVA; for oeeludin, *P
< 0.05 vs. HI-12h, HI-24h, and HI-48h, ANOVA). Vertical bars indicate SEM. N = 5 for
each group.
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Long Term Effects of MMPs Inhibition
Body weight and brain atrophy were assessed at 2 weeks post HI, while
neurological deficits were measured over a period of 7 weeks post HI to determine
whether the effect of GM6001 treatment is long-lasting.
No Improvement on Body Weight after MMPs Inhibition
There was a significantly loss of body weight in the HI group starting from 1 day post
HI and persisting till 2 weeks after injury (Figure 20). However, GM6001 didn't improve
the body weight, since there was no significant difference compared with HI group
(Figure 20, P > 0.05). Also, there was no significant difference in body weight between
sham and sham+GM6001 group.
MMPs Inhibition Reduces Brain Atrophy 2 Weeks Following Neonatal HI
A significant loss of ipsilateral brain tissue was seen in the HI group at 2 weeks
post HI, and it was attenuated after GM6001 treatment (Figure 21). To further quantify
the tissue loss, the ipsilateral and contralateral hemisphere tissue mass (g) was measured
and it demonstrated a significant reduction in the HI group after injury compared to the
sham group (Figure 21, HI vs. sham = 0.28 ± 0.02 vs. 0.51 ± 0.005, #P < 0.05, ANOVA).
However, there was a 20% reduction of brain tissue loss in the GM6001-treated group
(Figure 21, HI vs. H1+GM6001 = 0.28 ± 0.02 vs. 0.38 ± 0.03, *P = 0.004, ANOVA).
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Figure 20. Body weight in 2 weeks post HI. Daily body weight of rat pups from
age of 7-day to 21-day was shown in sham, sham+GMbOGl (100 mg/kg), HI, and
HI-I-GM6001 (100 mg/kg) groups. The body weight was significantly reduced in
HI group compared with sham group (P < 0.01, repeated measures ANOVA).
GM6001 treatment did not improve the body weight after HI injury (P > 0.05,
repeated measures ANOVA). No significant difference between sham and
sham+GMbOOl group. N = 9 animals for sham group. N = 8 animals for
























Figure 21. Brain atrophy at 2 weeks post HI. Top view of the brain
was shown from sham, sham+GMbOOl (100 mg/kg), HI and
HI+GM6001 (100 mg/kg) groups at 2 weeks after HI injtiry. There
was a significant tissue loss in the ipsilateral hemisphere in HI
group (#P < 0.05 vs. sham and sham+GM600l). Brain atrophy in
ipsilateral hemisphere was attenuated after GM6001 treatment (*P
= 0.004 vs. HI, ANOVA). The data was expressed as the brain
hemisphere tissue mass. N = 10 animals for sham group. N = 8
aninaals for sham+GM6001 group. N = 12 animals for HI group. N
= 11 animals for HI+GM6001 group, ns = no significance. Vertical
bars indicate SEM.
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MMPs Inhibition Improves Neurological Function against Neonatal HI in the 2
Weeks Following HI
Open field test was performed on the pups from age of day 12 to day 20. Total
moving distance, % time spent moving, and walking speed was analyzed from the 30-
minute moving activity of the rat pups. Total moving distance was increased with age
until PI5, and then gradually decreased to the baseline in all three groups (Figure 22A).
GM6001 treatment prevented the Hl-induced hyperactivity and significantly reduced
both total moving distance and % time spent moving (Figure 22A and 6B, P = 0.013 and
P < 0.01 respectively) later than age of 15 days following HI injury. There was no
significant difference on walking speed (data not shown). No significant difference was
seen between sham and sham+GM6001 group during open field test.
Cylinder test was performed at 2 weeks after HI injury (Figure 23). Animals in
sham and sham+GM6001 group showed symmetrical use of bilateral forelimb, while
animals in HI group showed marked asymmetry of forelimb usage due to the preference
for the non-impaired paw (right forelimb). The right forelimb usage was significantly
increased in the HI group compare to the sham group (Figure 23, #P < 0.05, ANOVA).
GM6001 treatment significantly reversed the asymmetry of forelimb usage and
significantly reduced the right paw usage compared to the animals in HI group (Figure 23,
*P < 0.05, ANOVA). There was no significant difference of forelimb usage between
sham and sham+GM6001 group.
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Morris Water Maze Test at 7 Weeks Post HI
Morris water maze test was performed at 7 weeks after HI injury. The swimming
latency (time required from releasing point to reach the platform) data on the cued and
spatial maze are shown in Figure 24A and 24B. The swimming latency (s) was reduced
after training in all the groups. No significant difference in swimming latency among all
the groups on the cued maze test (Figure 24A, P > 0.05, repeated measures ANOVA).
However, on the spatial maze test, the latency in the HI group was significantly increased
compare to all the other groups (Figure 24B, *P < 0.001, ANOVA).
The probe trial was performed after the spatial maze training. Animals in sham
group and sham+GM6001 group had about 4 times platform crossings to the target
quadrant on the test. No significant difference was observed between sham and
sham+GM6001 group. The crossings were reduced in the HI group and there is a trend
that GM6001 treatment increased the crossings, however, there is no significant
difference among all the groups. % total duration in the target quadrant was plot instead.
Animals in the sham and sham+GM6001 groups spent about 30% time in the target
quadrant, while it was significant reduced in the HI group (HI vs. sham = 22.02% ±1.31
vs. 29.56% ± 1.34, #P < 0.001; HI vs. sham+GM6001 = 22.02% ±1.31 vs. 28.7% ± 1.07,
#P < 0.001, ANOVA). GM6001 treatment increased the % total duration (HI vs.
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Figure 22. Open field test in the 2 weeks following HI. Open field test was used to
evaluate the locomotor activity for the animals from pl2 to p20 following HI injury.
Total moving distance (A) and % time spent moving (B) were increased after HI.
GM600I treatment prevented the Hl-induced hyperactivity and significantly reduced
both total moving distance and % time spent moving (P = 0.013 and P < 0.01 respectively,























Figure 23. Cylinder test at 2 weeks following HI. Right forelimb usage was
significantly increased compared to the sham group (#P < 0.05 vs. sham and
sham+GM6001, ANOVA). GM6001 treatment significantly decreased the
functional asymmetry (*P < 0.05 vs. HI, ANOVA). N = 9 animals for sham group.
N = 8 animals for sham+GM6001 group. N = 10 animals for HI group. N = 10
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Figure 24. Morris water maze at 7 weeks following HI. Sham group n=9; sham+GM6001
group n=8; HI group and HH-GM6001 group n=10. (A) Cued maze test. The latency (s)
is the time for rats to reach the visible platform. The latency was not significant in any of
the groups. (B) Hidden maze test. The latency (s) of HI group was significantly different
with all the other groups (*P < 0.001, ANOVA). (C) Probe trials for platform crossing
frequency. There was a trend of better performance in HI+GM6001 group compared with
HI group; however, it was not significantly different. (D) Probe trials for total duration in
the target quadrant. There was a reduced duration in the target quadrant for HI group (#P
< 0.05 vs. sham, ANOVA), and GM6001 treatment increased the total duration (*P =
0.01 vs. HI, ANOVA).
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Discussion
The present study showed that MMPs inhibition reduced BBS breakdown,
ameliorated brain edema, attenuated brain tissue loss after hypoxic-ischemic brain injury
in neonates. It is the first time to show that early MMPs inhibition has a long-term
neuroprotection against neonatal HI injury.
MMPs are synthesized and secreted as proenzymes that require convert to active
form for biological activity. GM6001 is a peptidyl hydroxamate inhibitor which binds to
the active sites of MMPs (Schultz et al. 1992) and prevents the conversion of pro-MMPs
to active forms of matrix-degrading MMPs (Hao et al. 1999). Doxycycline has been
shown to inhibit MMPs activity successfully in the brain (Burggraf et al. 2007). The
possible mechanisms of doxycycline-induced MMPs inhibition include direct
transcriptional inhibition due to blockage of the activating protein factor-1 (Hanemaaijer
et al. 1998), chelation of Zn^"^ or Ca^"^ thus blocking the active site of MMPs (Golub et al.
1998), or blockage of MTI-MMP-induced pro-MMP activation (Lee et al. 2001).
Previous studies showed doxycycline has effects on neutrophil suppression (Gabler and
Creamer 1991), caspase-3 inhibition and suppression of microglial activation (Jantzie et
al. 2005). Since MMPs inhibition might be only one of the possible neuroprotective
mechanisms provided by doxycycline, we would like to choose a more specific MMPs
inhibitor (GM6001) to further study the neuroprotective mechanisms and the long-term
effects after MMP inhibition in neonatal HI brain injury.
MMPs activities are inhibited by their endogenous TlMPs. The imbalances
between MMP-9 / TlMP-1 and MMP-2 / TlMP-2 may result in an increased proteolytic
activity thus lead to detrimental effects in the brain. Our data suggested that both MMP-2
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and MMP-9 were activated after HI injury, and the activation of MMP-9 was earlier than
MMP-2 activation. Interestingly, their endogenous inhibitors, TIMP-1 and TIMP-2, were
also increased after HI injury. The induction of TIMP-1/-2 may suggest the endogenous
neuroprotection against HI insult, since they inhibited MMP-2/-9 activation. Meanwhile,
studies showed that TIMP-1 provided neuroprotection against excitotoxicity which was
independent of MMP inhibition (Tan et al. 2003). However, the elevation of TIMP-1 was
delayed compare to MMP-9 activation. Meanwhile, the level of MMP-9 after HI injury
was much more extensive than the level of TIMP-1 at 12 h to 24 h post HI, which
suggested that TIMP-1 expression only partially inhibited the MMP-9 activation at the
acute stage after neonatal HI injury. The mismatch of MMP-9 / TIMP-1 elevation and the
increased ratio of MMP-9 / TIMP-1 (data not shown) could be partially responsible for
the brain damage in the immature brain. Meanwhile, the levels of MMP-2 and TIMP-2
were comparable after HI injury, and the temporal profiles of MMP-2 / TIMP-2 were
parallel with the similar smge time point. It may provide some explanations why MMP-2
is less responsible for the brain damage compared to MMP-9 (Asahi et al. 2001a). Since
electrophoresis separated TIMP-1/-2 from MMP-2/-9 when using gelatin zymography,
the MMP-2/-9 activity in Figure 16 reflects the expression of act-MMP-2/-9, not the ratio
of act-MMP-9/TIMP-l or act-MMP-2/TIMP-2 (Figure 17). In consistent with the
previous report (Park et al. 2009), the proMMP9 level was increased 24 h after HI injury
as compared to the sham level (data not shown). Future study is required to investigate
the pro-MMPs and their transcriptional levels after HI injury. It is unexpected that TIMP-
1/-2 expression was decreased after GM6001 treatment. Previous reports have
documented that inflammatory cytokines (such as IL-ip, TNF-a, IL-6) are important to
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stimulate TIMPs expression (Bugno et al. 1999;Pagenstecher et al. 2000). It is possible
that the influence of GM6001 on TIMPs expression is due to the secondary effects by
GM6001-induced neuroprotection, instead of the direct effects. However, the regulation
of TIMPs genes expression after HI is complex and the responsible mechanisms remain
to be elucidated in the future study.
Our data showed that either GM6001 or doxycydine treatment was able to reduce
brain edema at 48 h after HI injury. The BBB opening in immature brain plays a vital role
in the severity of brain edema. Since endothelial cells and the end-foot of astrocytes are
the major structural components of BBB, to confirm the cell-types and sources of MMP-9
expression, double staining' for GFAP/MMP-9 and vWF/MMP-9 were performed on the
brain sections at 24 h after HI injury. Double-staining result showed that the MMP-9
expression was co-localized with both astrocytes and endothelial cells (Figure 18), which
was observed in the frontal cortex area. It suggests MMP-9 activation may have highly
association with BBB disruption. TJPs are a group of membrane proteins that form the
BBB and maintain its structural and functional integrity (Ballabh et al. 2004). Recent
studies suggested that MMPs affected BBB permeability by targeting TJPs in the adult
brain after focal ischemia (Yang et al. 2007). Our results showed that there was a
continuous degradation of ZO-1 and occludin in the neonatal brain starting 12 h after HI
injmy and the MMPs activation led to BBB opening in the brain via TJPs degradation.
MMPs inhibition could block this process and have a beneficial effect after HI injury.
It is reported that MMP-9 gene knock-out protected the immature brain against
cerebral hypoxia-ischemia via attenuating inflammation and reducing brain tissue loss
(Svedin et al. 2007). However, there is no information about the effects of MMPs
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inhibition on neurological function after HI in the developing brain. Meanwhile, MMPs
are involved in promoting neuroblast cells migration and neurovascular remodeling in the
delayed phase after injury (Lee et al. 2006;Zhao et al. 2006), which play beneficial role
during stroke recovery. It is interesting to evaluate the long-term effects after MMPs
inhibition in acute stage of neonatal brain injury. Current study for the first time showed
that early MMPs inhibition provided long-term neuroprotection on both morphology and
neurological fimction in the immature brain following HI. The hrain atrophy was reduced
2 weeks after HI in the GM6001-treated group. However, there was no improvement on
the body weight after GM6001 treatment. We also examined the sensorimotor, locomotor,
cued and spatial navigation function after HI injury. In consistent with previous report
(Fan et al. 2005), hyperactivity was present at age of 14-day to 16-day after HI injury,
which was correlated to learning and memory deficits (Nyakas et al. 1996). Both the
sensorimotor and locomotor deficits were improved after MMPs inhibition and two
injections of GM6001 at the early stage after HI had no effects on the normal brain
function, since all the neurobehavioral tests had there is no difference between sham and
sham+GM6001 groups. The latency in the water maze test was determined by both motor
and cognitive function (McAuliffe et al. 2006). No differences on cued maze latency
were shown among all the groups. Analysis of the latency on hidden maze test showed
that the performance by rats in HI group was significantly worse compare to sham and
sham+GMbOOl groups (*P < 0.001, ANOVA), which could be associated with the motor
deficit after HI injury. MMPs inhibition significantly reduced the latency on hidden maze
test. However, repeated measures analysis showed no difference among all the groups,
which suggested that the learning curve was not affected after neonatal HI injury.
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In conclusion, our results demonstrate that MMPs inhibition with a broad-spectrum
inhibitor provides both acute and long-term protection in the developing brain by





The data presented in the previous sections suggests that BBS protection via
either early HIF-1 inhibition or MMPs inhibition at the early stage after hypoxie-ischemic
injury is neuroprotective in the developing brain. Moreover, the beneficial effects are
long lasting which provide a long-term morphological and functional improvement.
Targeting HlF-1 and MMPs may provide to be an effective strategy for the prevention of
BBB breakdown and edema formation which will both reduce risk of death and improve
permanent disabilities after stroke in infants and children.
The Dual Role of HIF-1 in the Central Nervous System
In 1999, Bergeron et al. reported that HlF-1 activation in the brain after focal
ischemia may help tissue surviving in the penumbra area (Bergeron et al. 1999). On the
contrary, in the same year, Halterman et al. found that HlF-1 interacts with p53 and
promotes cell death in cortical neuronal cultures (Halterman et al. 1999). Since then, the
role of HlF-1 in the central nervous system has been studied widely, and controversy
studies have been reported that HlF-1 is a regulator of both prosurvival and prodeath
responses in the central nervous system. Helton et al. found that knockout of HlF-1 leads
to neuroprotective in response to acute hypoxia/ischemia (Helton et al. 2005). However,
in two years, Baranova et al. reported that neuron specific knockdown of HlF-la resulted
in increased tissue damage after focal cerebral ischemia (Baranova et al. 2007).
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The function of HIF-1 in the hrain might be both prodeath and prosurvival, which
could depend on follows: (1) the hypoxia duration and severity (Halterman and Federoff
1999). Mild hypoxia induces adaptive gene expression facilitating energy supply which
provides protection. Severe hypoxia leads to high levels of HIF-1 a and promotes death
genes expression, which results in the initiation of the delayed death process; (2) different
types of pathological stimuli (Aminova et al. 2005). Enhanced HIF-1 activity in
hippocampal neuroblast (HT22) cells leads to oxidative neuronal death following
glutathione depletion induced injury, whereas increased HIF-1 activity provides
neuroprotection after camptothecin-induced injury; (3) different cell types (Vangeison et
al. 2008). Vangeison et al. reported that knockdown of HIF-1 a in neurons results in
reduced neuronal viability following hypoxia; however, selective knockdown of HIF-1 in
astrocytes markedly protected neurons from hypoxic-induced neuronal death; (4) the
environmental state in the cell following the insult (Ratan et al. 2007). When the neuron
becomes acidotic or oxidized, the prodeath proteins such as BNIP3 will undergo a
conformational change thus activate cell death. On the contrary, if the survival genes are
effective in neutralizing the hypoxic stress, such as no acidosis or oxidative stress, the
death genes will never get activated.
Mechanisms of Neuroprotection by HIF-1 Inhibition
In our study, we used a HIF-1 inhibitor following neonatal hypoxic-ischemic
brain injury. Although currently there were various controversy reports about the function
of HIF-1 in the brain, our data suggests that acute HIF-1 a inhibition is protective in the
immature brain after HI injury. The observed neuroprotection could be associated with
the following mechanisms.
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(1) Early HIF-1 inhibition at the acute after neonatal HI injury. In our study HIF-
la inhibitor treatment at 3 h after HI failed to provide neuroproteetion, whereas HIF-1
inhibition immediately after injury protected brain injury. It might be associated with the
HIF-1 activation temporal profile, which is differentially regulated depending upon the
different types of stimuli, severity of the insult and the age of the animal. In a postnatal
12-day rat HI injury model, van den Tweel et al. reported that HIF-1 a proteins increased
and peaked at 3 hr but returned to baseline at 6 h post HI during the first 48 h after injury
(van den Tweel et al. 2006). The ineffectiveness of 2ME2 when administered at 3 h after
HI in the present study strongly suggests that nemoprotective effects are dependent on
early HIF-1 a inhibition i.e. before peak levels.
Moreover, the function of HIF-1 at the acute stage and the later stage post-HI may
be conducted by different mechanisms, as Baranova et al. suggests there is a biphasie
activation of HIF-la after focal stroke in the MCAo adult model (Baranova et al. 2007).
The initial phase correlated with the upregulation of HIF-1-targeted pro-death genes;
while during the later phase the HIF-la activation mediates the expression of genes that
are related to regenerative responses. It could be interesting to investigate, if the biphasie
HIF-la expression also exists after neonatal HI insult, the inhibition of HIF-la at later
time points which might have different effects.
(2) Down-regulate VEGF at the acute stage after HI injury. VEGF has dual effects
in the brain, while its function in the brain could be stroke-stage-dependent. VEGF can
promote angiogenesis and restore cerebral microvascular circulation, whereas it is also a
potent vascular permeability factor which could enhance the BBB leakage (Zhang et al.
2000). VEGF inhibition during early phase after stroke is likely to be favorable. It has
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been previously suggested that the inhibition of VEGF at the acute stage of stroke is
beneficial (Fagan et al. 2004), which is likely to be mediated through preservation of
BBB and attenuation of brain edema. It is also suggested that administration of VEGF at
a late stage of stroke provides neuroprotection while administration of VEGF early after a
stroke increases BBB leakage (Zhang et al. 2000). The neuroprotection in the present
study may be due to VEGF down-regulation at an early stage of stroke by acute HIF-1
inhibition. However, it is possible that VEGF reduction in this study may be a collateral
effect, accompanied by the inhibition of a multitude of HIF-1-targeted-genes involved in
glycolysis, inflammation, apoptosis, and proteolysis.
(3) General HIF-1 inhibition instead of cell-type specific HIF-1 inhibition. Recent
study by Vangeison et al. suggests that selective loss of HIF-1 a function in astrocyte
cultures provides intensive neuroprotection from hypoxia, whereas loss of neuronal HIF-
la increases neuronal susceptibility to hypoxia-induced damage (Vangeison et al. 2008).
It suggests that the pathological functions of HIF-1 a could be cell type specific. The
possible differential roles of HIF-1 in different cell types may provides partial
explanations for the divergent results from Helton et al., Baranova et al., and our
observations. Previous studies have described that different cell types, such as neurons,
astrocytes, and endothelial cells, could express HIF-lalpha (Chavez et al. 2000;Witt et al.
y
2005), Our data shows (Figure 11) HIF-lalpha positive staining in unspecified cells other
than endothelial cells, and it is likely that our treatment also inhibited HIF-1 a in these
cells as well. In our study, as well as the study by Helton et al., HIF-Ia inhibition
involved neuronal as well as non-neuronal cell types in the CNS, which may result in an
overall pathological role for HIF-1 a. Therefore, it is possible that the benefits of blocking
100
HIF-la across non-neuronal cell types outweigh the potential negative side effects of
neuron specific HIF-la blockade.
The Dual Role of MMP Following Stroke
Previous studies suggested that hypoxia-induced MMPs family activation is
exclusively regulated by HIF-1 (McMahon et al. 2005; Elstner et al. 2007). MMPs are
zinc-dependent endopeptidases which are capable pf degrading many types of
extracellular matrix proteins and involved in the process of BBB disruption, hemorrhage,
and brain edema formation. Stroke patients display significantly high levels of MMPs,
especially MMP-2 and MMP-9 (Montaner et al. 2001). The MMPs are expressed at a low
level in the basal conditions, whereas they are activated after acute CNS injury such as
ischemia (Gasche et al. 1999), hemorrhage (Rosenberg and Navratil 1997), and trauma
(Wang et al. 2000). MMPs inhibition in different adult stroke animal models has been
demonstrated to be beneficial on the outcomes. Specifically, it was found that MMPs
inhibitor was able to: (1) prevent the BBB opening and reduce the brain edema in a
transient MCA occlusion model (Rosenberg et al. 1998); (2) reduce brain infarct size in a
mouse model of permanent focal cerebral ischemia (Asahi et al. 2000); (3) significantly
reduce tissue plasminogen activator (tPA)-induced hemorrhage volume after embolic
focal ischemia injury by placing homologous blood clots into the MCA (Sumii and Lo
2002); (4) reduce the brain water and sodium contents in the brain and improve
neurological function after an intracerebral hemorrhage (Rosenberg and Navratil
1997;Wang and Tsirka 2005); (5) significantly reduce hippocampal neuronal damage
after global cerebral ischemia (Lee et al. 2004).
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Although MMPs have been shown to be involved in detrimental processes in the
acute phase after brain injury, such as degradation of neurovascular substrates and
anoikis-like brain cell death (Gu et al. 2002), there are also reported evidences showing
the beneficial role of MMPs during the delayed stages after brain injury. MMPs are
involved in matrix remodeling that permits axonal extensions and recovery after CNS
injury (Larsen et al. 2003;Reeves et al. 2003). Moreover, MMPs may mediate the
neurogenic migration from the subventrieular zone (SVZ) toward damaged brain area
(Lee et al. 2006). Delayed inhibition of MMPs from 7 days to 14 days after stroke is
deleterious, which results in reduction in neuronal plasticity and vascular remodeling and
additional tissue damage in peri-infarct cortex (Zhao et al. 2006). These data suggest that,
contrary to MMP inhibitor therapies for acute brain injury, some caution may be required
to modulate MMPs activity in the late stages of stroke.
Mechanisms of Neuroprotection by MMPs Inhibition
However, the role of MMPs in the developing brain has not been evaluated till
recently. In 2007, Svedin et al. showed that deletion of the MMP-9 gene reduces cerebral
tissue volume loss, protects the white matter, and attenuates inflammation in the
immature brain after a moderate HI insult (Svedin et al. 2007). The neuroprotection in
MMP-9 knockout (KO) animals after HI injury was associated with a delayed and
reduced opening of the BBB. Although MMP-9 knockdown has been demonstrated to be
protective in the immature brain after cerebral HI, it is still important to evaluate the
effects of MMPs inhibition using pharmacological interventions. Knockout approach may
cause compensatory changes in response to the primary effects of the mutation, which
might not be directly related to the mutation at a functional level but may reflect
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secondary changes (Gaetano Di Chiara et al., 2002). In vivo testing with pharmacological
agents, on the other hand, is a necessary step in the pre-clinical testing of therapeutics,
which are more readily to be transferred to testing in humans.
In our study, we used a broad-spectrum MMPs inhibitor at 2 h following neonatal
hypoxic-ischemic brain injury. After HI injury, both MMP-2 and MMP-9 were activated
after HI injury. Meanwhile, MMP-21-9 endogenous inhibitors, TIMP-1 and TIMP-2,
were also increased following insult, which may suggest the endogenous neuroprotection
against HI injury. However, the elevation of TIMP-1 was delayed and less extensive
compare to MMP-9 activation, which suggested that TIMP-1 only partially inhibited the
MMP-9 activation at the acute stage after neonatal HI injury. The mismatch of MMP-9 /
TIMP-1 elevation and the increased ratio of MMP-9 / TIMP-1 could be partially
responsible for the brain damage in the immature brain. GM6001 is a peptidyl
hydroxamate inhibitor which binds to the active sites of MMPs (Schultz et al. 1992) and
prevents the conversion of pro-MMPs to active forms of matrix-degrading MMPs (Hao et
al. 1999). Our results showed that GM6001 treatment (100 mg/kg) blocked MMP-21-9
activation at 24 h and 48 h post HI.
Moreover, the degradation of TJPs, including both ZO-1 and occludin, was
significantly preserved in the ipsilateral hemisphere at 48 h after MMPs inhibition. TJPs
in endothelial cells are a major structural component of BBB formed by components of
the neurovascular unit. MMP-9 can digest several matrix proteins in the vascular basal
lamina including collagen, fibronectin, and laminin. It leads to the damage of vascular
integrity thus disrupt blood- brain barrier function and increase vasogenic edema. Earlier
studies suggested that MMP-2 played a key role in the initial opening of the BBB in rat
brain (Rosenberg et al, 1998). Moreover, TJPs disruption is reversed by MMP inhibitor
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in a focal ischemia adult rat model (Yang et al. 2006). The observed neuroprotection by
MMPs inhibition in our study could be associated with reducing TJPs degradation,
preserving BBB integrity, and ameliorating brain edema.
However, there are also evidences suggest that MMPs are involved in intracellular
proteolytic cell death mechanisms (Gu et al. 2005), inflammation processes (Schonbeck
et al. 1998), cleaving and releasing matrix-bound isoforms of VEGF (Bergers et al. 2000),
and anoikis-like cell death (Lee et al. 2008). Therefore, other than BBB protection,
MMPs inhibition may provide neuroprotection via multiple pathways which will require
further study in the future.
Long-Term Effects of MMPs Inhibition in the Developing Brain
In agreement with previous report from Svedin et al., we found that MMPs are
deleterious in the immature brain at the acute stage after HI injury. However, there is no
information about the effects of early MMPs inhibition on neurological function after HI
in the developing brain. Our data for the first time showed that early MMPs inhibition
' provided long-term neuroprotection on both morphology and neurological function in the
immature brain following HI.
Similar to other studies (Calvert et al. 2002;Bona et al. 1997), we found that the
brain tissue loss and atrophy were accompanied in the development of immature brain at
the late stage after HI injury. In contrast, animals that were treated with MMPs inhibitor
experienced less brain damage and tissue loss. Since the brain tissue loss can hamper
certain areas of the brain thus resulting in a number of neurological handicaps, we
evaluated the effects of MMPs inhibition on locomotor, sensorimotor, and cognitive
function following HI injury. We found that animals treated with MMPs inhibitor scored
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better than the Hl-injnred animals at open field test, cylinder test, and Morris water maze
test. Those findings demonstrate that MMPs inhibition at the acute stage after HI injury
in the immature brain is able to attenuate the locomotor, sensorimotor, and cognitive
deficits caused by HI insult at the long term stage. Moreover, there is no difference
between sham animals and sham animals with MMPs inhibitor treatment during all the
neurological behavioral testing, which suggests that two dosages of MMPs inhibitor
administration did not affect the normal immature brain development and its long term
neurological function. The findings may provide to be a promising therapeutic strategy
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